

CURRICULUM VITAE

BIOGRAPHICAL

NAME: Donald L. Trump, MD **BIRTH DATE:** July 31, 1945

HOME ADDRESS: 230 North Street, C6 **BIRTH PLACE:** Greencastle,
Buffalo, NY 14201 Indiana

HOME PHONE: (716) 704-2535 **CITIZENSHIP:** United States

BUSINESS ADDRESS: Roswell Park Cancer Institute
Elm & Carlton Streets
Buffalo, New York 14263 **EMAIL:** donald.trump@roswellpark.org

BUSINESS PHONE: (716) 845-8501 phone
(716) 845-8261 FAX

EDUCATION AND TRAINING

UNDERGRADUATE:

1963-1967 The Johns Hopkins University B.A. Human Biology
Baltimore, MD 1967

GRADUATE:

1966-1970 The Johns Hopkins University M.D.
School of Medicine 1970
Baltimore, MD

POST GRADUATE:

1970-1971 The Johns Hopkins Hospital Intern, Dept. of Medicine
Baltimore, MD

1971-1972 The Johns Hopkins Hospital Junior Assistant Resident,
Baltimore, MD Dept. of Medicine

1972-1973 The Johns Hopkins Hospital Senior Assistant Resident,
Baltimore, MD Dept. of Medicine

1973-1974 The Johns Hopkins Oncology Fellow, Oncology Center
Baltimore, MD

1974-1975 The Johns Hopkins Hospital Chief Resident,
Baltimore, MD Dept. of Medicine

APPOINTMENTS AND POSITIONS

ACADEMIC:

1974-1975 The Johns Hopkins University School of Instructor, Dept. of Medicine,
Medicine, Baltimore, MD

1976-1977 Thomas Jefferson University School of Clinical Assistant
Medicine, Philadelphia, PA Professor of Medicine

1977-1981 The Johns Hopkins University School of Assistant Professor,
Medicine, Baltimore, MD Dept. of Medicine

1977-1981 The Johns Hopkins Oncology Center Assistant Professor,
Baltimore, MD Oncology

1981-1984 University of Wisconsin Assistant Professor,
Madison, WI Dept. of Human Oncology

1981-1984 University of Wisconsin Assistant Professor,

1984-1988	Madison, WI University of Wisconsin Madison, WI	Dept. of Medicine Associate Professor, Dept. of Human Oncology
1984-1988	University of Wisconsin Madison, WI	Associate Professor, Dept. of Medicine
1988-1992	Duke University Medical Center Durham, NC	Professor, Dept. of Medicine
1992-2002	University of Pittsburgh School of Medicine Pittsburgh, PA	Professor Depts. of Medicine and Urology
1992-2002	University of Pittsburgh Cancer Institute Pittsburgh, PA	Deputy Director for Clinical Investigations
1996-1998	University of Pittsburgh School of Medicine Division of Medical Oncology	Chief
1998-2002	University of Pittsburgh School of Medicine Division of Hematology/Oncology	Chief
2002-2007	Department of Medicine Roswell Park Cancer Institute, Buffalo, NY	Chairman
2002-2007	Roswell Park Cancer Institute, Buffalo, NY	Senior Vice President Clinical Research
2002-present	Roswell Park Cancer Institute Buffalo, NY	Professor Molecular Pharmacology, Professor Oncology
2002-present	State University of New York at Buffalo	Professor of Medicine
2007-present	Roswell Park Cancer Institute, Buffalo, NY	President and Chief Executive Officer

HOSPITAL STAFF POSITIONS:

1975-1977	Staff Oncologist, Naval Regional Medical Center, Philadelphia, PA
1977-1981	Active Staff, The Johns Hopkins Hospital, Baltimore, MD
1981-1988	Active Staff, University of Wisconsin Hospitals and Clinics, Madison, WI
1981-1988	Staff Oncologist, William S. Middleton Veterans Administration Hospital Madison, WI
1981-1988	Consultant, Madison General Hospital, Madison, WI, and St. Mary's Hospital, Madison, WI
1988-1992	Active Staff, Duke University Medical Center
1992-2002	Active Staff, University of Pittsburgh Medical Center
1998-2002	Active Staff, UPMC-Shadyside
2002-present	Active Staff, Roswell Park Cancer Institute

BOARDS AND PUBLIC SERVICE

1993-1994	Board of Directors, American Cancer Society Greater Pittsburgh
2004-present	Board of Directors, Health Research Institute, New York State
2005-2007	Board of Directors, Upstate New York Transplant Center
2007-present	Board of Directors, (ex officio) Roswell Park Cancer Institute
2007-present	Board of Directors, American Association of Cancer Institutes
2008-present	Board of Directors, Buffalo Niagara Partnership
2008-present	Board of Directors, National Coalition for Cancer Research
2008-present	Buffalo Club, Membership Committee
2009-present	Member of clinical & Translational Research Committee – AACR
2009-present	Board Member, Fox Chase Cancer Center External Advisory Board
2009-present	Board Member, Johns Hopkins Cancer Guide Medical Advisory Board

CERTIFICATION AND LICENSURE

1973	Diplomate, American Board of Internal Medicine (ABIM)
1977	Subspecialty Boards, Medical Oncology (ABIM)
1987	Fellow, American College of Physicians

MEDICAL OR OTHER PROFESSIONAL LICENSURE:

Wisconsin
Maryland
North Carolina
Pennsylvania
New York

MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

1977-present American Association for Cancer Research
1979-2000 American Federation for Clinical Research
1978-present American Society of Clinical Oncology
1978-present American Association for the Advancement of Science
1976-1992 New York Academy of Science
1978-1988 The International Society for the Study of Lung Cancer
1987-1992 American Association for Cancer Education
1999-present Society of Urologic Oncology
2000-2002 America College of Physicians Executives
2000-present American Urological Association
1998-present Society for Basic Urologic Research
2007-present American Association for Cancer Research Science Policy and Legislative Affairs Committee

HONORS

American Cancer Society, Junior Faculty Fellowship 1977-1980
Who's Who in America, Science and Engineering 1991, 1994, 1996
Best Doctors in America 1994, 1999, 2002, 2003-2004, 2007-2008
Pittsburgh Vectors Person of the Year in Science 2001
Joseph Burchenal Lectureship, November, 2001
Memorial Sloan Kettering Cancer Institute
America's Top Doctors for Cancer 2005-2008
Johns Hopkins University Society of Scholars 2009

PROFESSIONAL ACTIVITIES

RESEARCH:

PEER-REVIEWED-ACTIVE:

Active:

P30-CA-016056-32 PI (Trump) 05/01/08 – 04/30/13
National Institutes of Health \$2,488,882
Cancer Center Support Grant

R21-CA-128193-01A1 Co-PI (Trump) 02/01/08 – 01/31/10
National Institutes of Health \$192,480
A Phase I/II Clinical Trial of Intravenous Calcitriol with Fixed Doses of Cisplatin and Docetaxil

PC-040238 PI (Trump) 09/28/04-03/31/10
Department of Defense \$128,099
Evaluation of CYP24 as a Target for Enhancing Vitamin D Analogue Activity in Prostate Cancer:
Preclinical and Clinical Studies.

R01-CA-095045-06 Co-PI (Trump) 09/15/08-07/31/13

National Cancer Institute Vitamin D in Prostate Cancer: Tumor Vasculature Effects	\$158,548
R01-CA-67267-14 National Cancer Institute Anti-Tumor Mechanisms and Therapeutic Effects of Vitamin D	Co-PI (Trump) 05/01/95-02/28/09 \$237,045
R01-CA-85142-08 National Cancer Institute Glucocorticoids and Vitamin D: Modulation of Anti-tumor Effects	Co-PI (Trump) 02/01/00-06/30/10 \$201,448
5U10-CA 059518-16 National Cancer Institute Cancer and Leukemia Group B: RPCI/SUNYAB	Co-PI (Trump) 04/15/93-03/31/09 \$171,300
<u>PEER REVIEWED – PAST:</u>	
R21-CA-113950-01 NIH Biomarkers for Diagnosis and Management of Prostate Cancer	Co-PI (Trump) 12/01/05 – 11/30/08 \$72,825
R01-CA-95367-05 National Cancer Institute Vitamin D Analogs for Chemoprevention of Prostate Cancer	Co-PI (Trump) 09/01/02-08/31/08 \$222,500
R21-CA-112914-02 NIH Evaluation of CYP24 as a Target for Enhancing Vitamin D Analogue Activity in Prostate Cancer: Preclinical and Clinical Studies.	PI (Trump) 02/01/05 – 01/31/08 \$192,859
1 S07 RR-18167-01 National Institutes of Health Implementation of Data Safety Monitoring Plan (DSMP)	PI (Trump) 09/01/02 – 08/31/05 \$99,447
Orphan Products Development FDA Calcitriol & Dexamethasone for Myelodysplastic Syndromes, IND#61,905	Co-PI (Trump) 10/01/01-09/30/04 \$282,639
R21-CA-93072-01 National Cancer Institute Vitamin D and Dexamethasone in Myelodysplastic Syndromes	Co-PI (Trump) 07/01/01-06/31/03 \$250,000
DAMD 17 98 1 8549 Department of Defense Modulation of Paclitaxel Antitumor Effects by Calcitriol: Modulation of Anti-Tumor Effects	PI (Trump) 10/1/98-04/30/01 \$120,529
5 U01 CA69855-03 National Cancer Institute Laboratory Studies for A Phase I Trial of 17 AAG	PI (Trump) 03/01/97-6/30/02 \$51,241
N01 HR96142 National Heart, Lung, & Blood Institute Clinical Centers for Feasibility Studies on Retinoid Treatment in Emphysema	Co-PI (Trump) 09/30/99-6/30/02 \$79,892
N01 CN 75018PI National Cancer Institute	PI (Trump) 02/15/97-6/30/02 \$502,825

MA042: Chemoprevention Studies in Prostate Cancer

1 P60 DE13059-01 National Institute of Dental Health Oral Cavity Cancer Center	Co-PI (Trump) 08/01/99-06/30/02 \$149,969
5 U01 CA69855-03PI National Cancer Institute Laboratory Studies of a Phase I Trial of 17 AAG	Co-PI (Trump) 03/01/97-06/30/02 \$51,241
U01-CA69855-03 National Cancer Institute Phase I Clinical Trials of Anticancer Agents	PI (Trump) 05/15/95-02/28/00 \$174,547
National Institutes of Health Phase I Clinical Trials of Anticancer Agents	PI (Trump) 03/01/97-02/28/99 \$188,870
National Institutes of Health Drug Metabolizing Enzymes: Risk Factors in Bladder Cancer	Co-PI (Trump) 07/01/94-04/30/99 \$125,394
National Institutes of Health Cancer Center Support Grant	Co-PI (Trump) 09/01/95-07/31/99 \$1,093,387
National Institutes of Health Cancer Center Support Grant	Co-PI (Trump) 08/01/88-07/31/99 \$68,812
National Institutes of Health Education Resource for Tumor Heterogeneity	PI (Day) 04/01/96-03/31/97 \$233,322
National Institutes of Health Breast Cancer Research Program at UCPI	Co-PI (Trump) 09/39/94-09/29/96 \$356,485
National Institutes of Health Therapeutic Studies of Primary CNS Malignancies in Adults	Co-PI (Trump) 03/18/94-12/31/97 \$40,837
National Institutes of Health Primary Breast Cancer Therapy: NSABP	PI (Trump) 12/01/76-01/31/97 \$245,727
National Cancer Institute Gene Specific Therapy of Breast and Pancreatic Cancer NCDDG	PI (Trump) 08/92 - 07/96 \$2,872,732
U10-CA39088 National Institutes of Health-Frontier Science WI Eastern Cooperative Oncology Group Cooperative Group Outreach	PI (Trump) 12/01/85-11/30/87 \$23,810
NO1-CM 57735 National Institutes of Health Clinical Development of Anticancer Agents	PI (Trump) 07/01/83-11/30/88 \$93,463
CA39088WI National Institutes of Health -Frontier Science Eastern Cooperative Oncology Group Wisconsin Studies	Co-PI (Trump) 06/01/78-04/30/89 \$240,581

H P30-CA14520-14 National Institutes of Health; Cancer Center Support (Comprehensive)	Co-PI (Trump)	01/01/78-07/31/89 \$1,462,564
Food and Drug Administration Clinical Study of t-Retinoic Acid in Prostate Cancer	Co-PI (Trump)	09/92-09/05 \$240,581
National Cancer Institute Spore in Gastrointestinal Cancer	Co-PI (Trump)	09/93-09/95 \$137,917
<u>OTHER FUNDING:</u>		
CaPCURE Vitamin D: Clinical Studies in Prostate Cancer.	PI (Trump)	01/01/01-12/31/03 \$150,000
CaPCURE Treatment Consortium	PI (Trump)	11/95-10/31/00 \$150,000
CaPCURE Clinical and Preclinical Evaluation of 1,25 Dihydroxyvitamin D3- in Combination with Paclitaxel in Pro Vitamin D has important effects on the normal rat prostate: it inhibits the proliferation of human and rat prostate cancer and potentiates in vivo efficacy of paclitaxel as well as other cytotoxics.	PI (Trump)	01/01/98-12/31/00 \$100,000
CaPCURE Innovative Clinical Trials in Prostate Cancer	PI (Trump)	01/01/99-12/31/00 \$150,000
Mary Hillman Jennings Foundation Trial of Calcitriol in Localized Prostate Cancer: Investigation of Biologic Effects and Patient Endpoints	PI (Trump)	12/15/97-12/31/00 \$80,000
Aronex Pharmaceuticals, Inc. Phase II Open Label Trial to Assess Safety and Efficacy of Atragen in the Treatment of Hormone Refractory Prostate Cancer	PI (Trump)	03/01/99-02/28/01 \$82,342
Aronex Pharmaceuticals, Inc. Animal Studies Effects of Atragen alone or in combination with vitamin D In the Dunning rat prostate model system	Co-PI (Trump)	08/18/98-12/31/00 \$44,871
Ilex Pharmaceutical Pre-clinical studies to evaluate ILX23-7553 and cytotoxic Drugs in prostate and lung model systems	PI (Trump)	05/27/98-06/30/01 \$52,203
H3U-MC-JPAB Eli Lilly Company Evaluation of Escalating Doses of LY300502 Given Orally Patients with Metastatic Prostate Cancer	PI (Trump)	05/01/97 -10/31/00 \$44,717
B9E-MC-JHBB Eli Lilly Company Gemcitabine-A Phase II Study in Patients with Hormone Refractory Prostate Cancer	PI (Trump)	02/01/97-07/31/00 \$37,333
Bristol Meyers-Squibb Gemcitabine Plus Carboplatin and Paclitaxel for Patients with Metastatic Cancer with and without G-CSF	PI (Trump)	09/01/97-08/31/00 \$65,625

EB1089 LEO PHARMACEUTICALS INC. Efficacy and Safety of EB1089 Enteric-Coated Capsules (5mg) or Placebo in Patients with PSA 2-20mg/ml	PI (Trump)	09/01/98-08/31/00 \$80,000
VITD 102 Ilex Pharmaceutical A Phase I Study of ILX23-7553 Administered Orally on Three Consecutive Days and Repeated Weekly as	PI (Trump)	09/15/99-09/14/01 \$133,425
LGD1069-22 Ligand Pharmaceuticals Evaluation of Targretin Capsules in Patients with Metastatic, Androgen-Independent Prostate Cancer	PI (Trump)	10/01/96-09/30/00 \$29,058
CaPCURE Calcitriol effects on tumor-derived endothelial cells: therapeutic potential for prostate cancer.	Co-PI (Trump)	01/01/01-12/31/03 \$150,000
Bristol-Myers Squibb Clinical and pre-clinical studies to evaluate vitamin D in combination with paclitaxel.	PI (Trump)	09/01/98-08/31/01 \$100,000
Aventis Pre-clinical evaluation of vitamin D and Docetaxel in Tumor model systems	Co-PI (Trump)	09/01/98-08/21/01 \$60,588
Novacea The effect of DN 101 in pancreatic cancer	Co-PI (Trump)	06/17/04-12/16/06 \$100,000
PC 970578 Department of Defense Modulation of paclitaxel antitumor effects by calcitriol pre-clinical and clinical studies of mechanisms, toxicity And efficacy in prostate cancer	PI (Trump)	1998-2001 \$125,000

PENDING GRANTS:

Creativity Award Prostate Cancer Foundation Epigenetics: New Therapeutic Targets for Prostate Cancer	Co PI (Trump)	02/1/09-01/31/20 \$150,000
--	---------------	-------------------------------

PATENTS:

“Use of Pretreatment Chemicals to Enhance Efficacy of Cytotoxic Agents”

Johnson, C.S. and Trump, D.L., Inventors.

US Patent # 6,087,350.

European Patent #1 030 670.

Japanese Patent #517705/2001

“Endothelial Specific Targeting”

Wong, M.K., Modzelewski, R.A., Brown, C.K., Johnson, C.S. and Trump, D.L. - Inventors.

US Patent # 09/810,700

“Method of Treating Solid Tumors and Leukemias Using Combination Therapy of Vitamin D and
Anti-Metabolic Nucleoside Analogs”

Johnson C.S. and Trump D.L. - Inventors.

US Patent Pending

RESEARCH: INVESTIGATOR INITIATED CLINICAL TRIALS:

1. "Phase I Trial of Interleukin-1 alpha (DN) and Cyclophosphamide" Trump DL, Principal Investigator; Johnson CS, Smith D, Colvin M, Branch R, and Logan TF, Co-Principal Investigators (closed).
2. "Phase I Trial of Interleukin-1 alpha and Carboplatin in Patients with Metastatic Disease of the Lung: Effects on Tumor Blood Flow Evaluated by Positron Emission Tomography (PET)" Logan TF, Principal Investigator; Mintun MA, Kirkwood JM, Virji MA, Billiar T, Trump DL, Smith D, and Johnson CS, Co-Principal Investigators (closed).
3. "Phase II Trial of Suramin in Relapsed or Metastatic Head and Neck Cancer" Jacob HE and Johnson JT, Principal Investigators; Eibling D, Blakowski S, Belani CP, Johnson CS, Grandis J, Barnes EL, DeSantis M, Trump DL, Co-Investigators (closed).
4. "A Phase I Trial of Subcutaneous Calcitriol [1,25-(OH)₂D₃] and Suramin in Advanced Solid Tumors" Trump DL, Principal Investigator; Johnson CS, R. Branch R, Adedoyin A, Agarwal S, Lemberski B, Belani C, Osborn J, Hadid V, Smith DC, Getzenberg R, Muindi J, Hofacker J and Egorin MJ, Co-Investigators (closed, never activated).
5. "A Phase I Trial of Subcutaneous Calcitriol [1,2-(OH)₂D₃] and Steroids in Advanced Solid Tumors" D.C. Smith, Principal Investigator; Johnson CS, Trump DL, Branch R, Dwight Stiff and T. Whiteside T, Co-Investigators (closed and completed).
6. "A Phase I Trial of Subcutaneous Calcitriol [1,25-(OH)₂D₃] and Carboplatin in Advanced Solid Tumors" Trump DL, Principal Investigator; Brufsky A, Belani Muindi J, Hadeed V, Light B, Freeman C, Hofacker J, Egorin MJ and Johnson CS, Co-Investigators (closed and completed).
7. "A Phase I Trial of Oral Calcitriol [1, 25 (OH)₂ D₃] and Paclitaxel in Advanced Solid Tumors" Trump DL, Principal Investigator; Belani C, Johnson CS, Muindi J, Logan T, Brufsky A, Freeman C, and Egorin MJ, Co-Investigators (closed and completed).
8. "Phase I study of 1,25 dihydroxycholecalciferol (calcitriol) plus dexamethasone in hormone refractory prostate cancer." Trump DL, Principal Investigator; Long GS, Hofacker J, Brufsky A, Logan AT, Johnson CS, Co-Investigators. (closed and completed).
9. "Phase I study of oral 1,25 dihydroxycholecalciferol (calcitriol) and dexamethasone in hormone-refractory prostate cancer" (UPCI 99-044) Trump DL, Principal Investigators: Johnson CS, Egorin M, Belani C, Long CS, Wong M, Kim, Baar HJ, Brufsky A, Co-Investigators (closed and completed).
10. "Bone loss in older men and men with prostate cancer: A survey" (UPCI-00-010) Trump DL, Principal Investigator, Greenspan S, Johnson CS, Brufsky A, Long S, Wong and Nelson MJ, Co-Investigators. (closed and completed).
11. "Calcitriol plus dexamethasone in early, recurrent prostate cancer following local therapy" (UPCI – 00-034) Trump DL, Principal Investigator, Nelson J, Hrebinko JR, Johnson CS, Long S, Wong M, Brufsky A, Stoller R, Jacobs S, Rovee K, D. Potter D, Co-Investigators (closed and completed).
12. "Phase I and Phase II study of calcitriol, docetaxel, dexamethasone and zoledronic acid in patients with androgen-independent prostate cancer" Trump DL, Principal Investigator, Long GS, Wong M, A. Brufsky A, Nelson J, Johnson CS, Egorin MJ, Zamboni W, Potter D, Polakowski S, Co-Investigators (closed).
13. "Phase II Study of 1,25 dihydroxycholecalciferol (calcitriol) + dexamethasone in advanced head and neck cancer" (UPCI –99-125) Agarwala S, Principal Investigator, Trump DL, Johnson CS, Long GS, Johnson J, Myers E, Grandis J, Muindi J, Jeong J, Co-Investigators (closed).
14. "A Phase I study of ILX23-7553 administered orally once daily on three consecutive days and repeated weekly as single agent or in combination with dexamethasone to patients with solid tumors" (UPCI-99-079). Trump DL, Principal Investigator, Johnson CS, Muindi J, Wong M, Long GS, Brufsky A, Potter D, Co-Investigators (closed, study terminated).
15. "A pharmacokinetic and feasibility assessment of PC-SPES and docetaxel" Trump DL, Principal Investigator, Ahmed S, Pan SS, Egorin MJ, Brufsky A, Wong M, Johnson CS, Stoller R, Friedland D, Hrebinko R, Nelson J, Potter D, Co-Investigators (closed, never open).
16. "A Phase II trial of oral calcitriol [1,25-(OH)₂ Vitamin D₃] protocol for adult myelodysplastic syndrome" S. Savona, Principal Investigator, Trump DL, Johnson CS, Redner RL, McQuire E, Muindi J, Potter D, Co-Investigators (active).
17. "A phase I study of intravenous (iv) calcitriol in combination with ZD1839 (Iressa) in refractory solid tumors" Fakhri MG, Principal Investigator, Trump DL, Johnson CS, Javle M, Creaven P, Levine E, Loewen G, Ramnath N, Schwarz J, O'Connor T, Pendyala L, Egorin M, J. Kepner J, Regal L, Co-

- Investigators. (active).
18. "Phase I and phase II study of intravenous calcitriol, docetaxel and dexamethasone in patients with androgen-independent prostate cancer" Trump DL, Principal Investigator, Johnson CS, Levine E, Huben R, Pendyala L, Kepner J, Mogford J, Co-Investigators. (closed).
 19. "A Pilot Trial of Calcitriol in Localized Prostate Cancer: Investigation of Biologic Effects and Potential Intermediate Endpoints" Trump DL, Principal Investigator; Johnson CS, Huben R, Wong M, Slocum H, Muindi J, Levine E, Mohler J, Co-Investigators. (active).
 20. "A Phase I Study of intravenous (IV) calcitriol in combination with ketoconazole in refractory solid tumors" Trump DL, Principal Investigator, Fakhri MG, Johnson CS, Javle M, Creaven P, Levine E, Wong M, Ramnath N, Schwartz J, O'Connor T, Janarthan B, Iyer R, Co-Investigators. (active).
 21. "Phase II study of weekly intravenous 1,25 dihydroxycholecalciferol (calcitriol) + dexamethasone in androgen independent prostate cancer" Trump DL, Principal Investigator, Levine E, Wong M, Janarthan B, Johnson CS, Muindi J, Co-Investigators. (active).
 22. "Phase II trial of dexamethasone (4mg QDX4, D1-4 weekly) in combination with IV calcitriol (D2 weekly) in men with androgen independent prostate cancer" Trump DL, Principal Investigator; Mohler J, Johnson CS, Wong M, Levine E, Muindi J, Co-Investigators. (active).
 23. "Peroxiredoxins (Prxs) and Vitamin D Receptor (VDR) in Relation to Breast Cancer Prognosis: Tissue Levels and SNPs" Ambrosone CB, Principal Investigator; Yang J, Trump DL, Johnson CS, Park Y-M, McCann S, Hicks D, Edge S, Cheney R, Kulkarni S, Millen A, Yu J, Co-Investigators. (pending review).

REVIEWER FOR:

Abstracts in Oncology
 AMA Drug Evaluations
 Cancer Research
 Annals of Internal Medicine
 Cancer Treatment Reports
 Journal of Clinical Oncology
 Archives of Internal Medicine
 Cancer
 Chest
 New England Journal of Medicine
 Journal of Pain and Symptom Management
 Oncology
 Cancer Chemotherapy and Pharmacology
 Investigational New Drugs
 Journal National Cancer Institute

EDITORIAL BOARD MEMBERSHIPS:

1990-present	Cancer Chemotherapy and Pharmacology
1994	Current Opinion in Oncology
1995-present	Revista Argentina de Oncologia
1998-present	Journal of Urologic Oncology
1998-2002	Editorial Board ONCOLOGY
1999-present	Editorial Board, Current Treatment Options in Oncology
2000-2003	PDQ Editorial Board, National Cancer Institute
2000-present	Editorial Board, Urologic Oncology
2000-present	Associate Editor, Clinical Cancer Research
2001-present	Editorial Board, Cancer Today
2002-present	Editorial Board, CURE
2002-present	Editorial Academy, International Journal of Oncology
2002-present	Editor-In-Chief ONCOLOGY
2003-present	Editorial Board, American Journal of Clinical Oncology
2004-present	Editorial Advisory Board, Oncology Practice Options

NATIONAL PEER REVIEW COMMITTEES

2003-2006	Member, NIH/NCI Scientific Review Group, CONC
2003-2006	Member, NIH/NCI Scientific Review Group, Subcommittee D

2000-2003 Permanent Member, Experimental Therapeutics 2, IRG
 1996-2000 Temporary Member, Experimental Therapeutics 2, IRG
 1994-1997 Committee H Cancer Clinical Investigations Review Committee [CCIRC], NCI
 1995-1996 American Cancer Society, Clinical Investigations Award Committee
 1992-1995 Member, American Cancer Society (National) Committee on Clinical Awards
 1992 Reviewer, Grants Section, Alberta Medical Advisory Board
 1991 Reviewer, Grants Section, Alberta Cancer Board, Alberta, Canada
 1985-1986 Member, Technical Review Committee, State of Nebraska Cancer and Smoking Disease Research Program
 1988 Ad Hoc Reviewer, Experimental Therapeutics-2 Study Section, NCI
 1989 Reviewer, Veterans Administration Merit Review Board for Oncology

SERVICE:

1976-1977 Director, Tumor Registry, Philadelphia Naval Regional Medical Center, Philadelphia, PA
 1981-1988 Chief, Oncology Section, William S. Middleton Memorial Veterans Administration Hospital, Madison, WI
 1985-1988 Chief, Section of Medical Oncology, Departments of Medicine and Human Oncology, University of Wisconsin, Madison

 1977-1981 Physician, Active Staff, The Johns Hopkins Hospital, Baltimore, MD
 1981-1988 Physician, Active Staff, William S. Middleton Memorial Veterans Administration Hospital, Madison, WI
 1981-1988 Physician, Active Staff, University of Wisconsin Hospitals, Madison, WI
 1978-1980 American Cancer Society, Baltimore City Chapter, Patient Services Committee Co-Chairman
 1978-1981 American Cancer Society, Maryland Division, Professional Education Committee, Chairman, Travel Grants Subcommittee
 1984-1988 Member, Professional Education Committee, American Cancer Society, Wisconsin Division
 1986-1988 Member, Board of Directors, American Cancer Society, Dane County
 1988-1992 Director, Experimental Therapy, Duke Comprehensive Cancer Center
 1989-1992 American Cancer Society, North Carolina Professional Education Committee
 1991-1992 Cancer Protocol Review Committee, Duke Comprehensive Cancer Center; Chair
 1988-1992 Steering Committee, Duke Comprehensive Cancer Center
 1989-1992 Executive Committee, Division Hematology/Oncology, Duke University Medical Center
 1990-1992 Institutional Review Board, Duke University Medical Center
 1990-1992 Pharmacy and Therapeutics Committee, Duke University Medical Center
 1991 American Society of Clinical Oncology, Program Committee
 1993-1998 Board of Directors, American Cancer Society Greater Pittsburgh
 1992-2002 Member, African American Outreach Advisory Council, UPCI
 1992-2001 Member, Executive Committee, Pittsburgh Cancer Institute
 1992-2001 Member, Function Imaging Research Committee, University of Pittsburgh Medical Center
 1992-2001 Chair University of Pittsburgh Cancer Committee
 1995-1999 Board Member, Hematology Oncology Associates of the University of Pittsburgh Cancer Institute

 1994-1995 Interim Executive Officer, National Surgical Adjuvant Breast and Bowel
 1998-present External Advisory Committee Member, University of Iowa Cancer Center.
 1999-2002 Board of Directors, The Hemophilia Center of Western Pennsylvania
 2000-present Member, External Advisory Board, Alvin J. Siteman Cancer Center, St. Louis, MO
 2000-present Member, External Advisory Board, UC Davis Cancer Center, Sacramento, CA
 2002-2003 Chair, Finance Committee, American Society of Clinical Oncology
 2003-present Member External Data Safety Monitoring Board, The Cancer Institute of New Jersey
 2003-present Chairman, GPC Biotech Inc. Data Monitoring Board
 2004-present Member External Scientific Board for the Cleveland Clinic Taussig Cancer Center BRTT application
 2004-present Member Novartis Oncology Gimitecan Advisory Board
 2006-present Board Member, Upstate New York Transplant Services, Inc.

HONORS, NATIONAL OFFICES

May, 2000 - May, 2003 - Secretary-Treasurer, American Society Clinical Oncology
July, 2000 - Lawrence D. Ellis Chair in Hematology/Oncology, Department of Medicine,
University of Pittsburgh School of Medicine

CONSULTANT APPOINTMENTS:

1980, 1983, 1986 - Oncology Consultant, Los Angeles County-University of Southern California
Comprehensive Cancer Center, Loma Linda University
1986-1988 - Consultant, Southwest Oncology Group, GU Committee
1986 - Consultant, Medical Oncology, Institute of Biomedical Sciences, Academia Sinica, Taiwan,
Republic of China
1987 - Consultant, Prostate Cancer Working Group, Organ System Coordinating Center, NCI
1987 - Consultant, U.S. Pharmacopeia Convention
1998 - Consultant, Highmark Blue Cross/Blue Shield - Hematology/Oncology Subcommittee of Pharmacy
and Therapeutics Committee.
2002- present - Medical Advisor, UsToo! Prostate Information & Support Groups of Western New York

CLINICAL RESEARCH ADMINISTRATIVE POSITIONS:

1978-1983 Medical Oncology Chairman of the Phase II Studies Committee, National Bladder Cancer
Collaborative Group A Member
1982-1988 Co-Chairman, Wisconsin Oncology Group
1983-1986 Chairman, Medical Oncology Committee, National Bladder Cancer Collaborative Group A
1983-1986 Executive Committee, National Bladder Cancer Collaborative Group A
1981-1985 GYN-GU Committee, Eastern Cooperative Oncology Group
1983-1986 Toxicity Monitor - GYN-GU Committee, Eastern Cooperative Oncology Group
1985-1988 Chairman, Genitourinary Cancer Committee, Eastern Cooperative Oncology Group
1984-1989 Member, Bladder Cancer Working Group, Organ System Coordinating Center, NCI
1986-1988 Member, Executive Committee, Eastern Cooperative Oncology Group
1988-1992 Member, Board of Directors Cancer and Acute Leukemia Group B (CALGB)
1988-1992 Member, Core Committee, Pharmacology and Experimental Therapeutics Committee
(CALGB)
1988-1992 Data-Base Chairman, GU Committee, Eastern Cooperative Oncology Group
1990-1992 Member, Core Committee, Breast (CALGB)
1990-1992 Member, Executive Committee, CALGB
1990-1992 Member, Audit Committee, CALGB
1990-1992 Member, Membership Committee, CALGB
1991-1992 Co-Chair, GU Working Group, CALGB
1992-2002 Chairman, Protocol Review Committee, Pittsburgh Cancer Institute, University of Pittsburgh
Medical Center
1992-2002 Co-Chairman, General Clinical Research Center Advisory Committee, University of
Pittsburgh Medical Center
1992-2002 Member, Breast Cancer Coordinating Committee, University of Pittsburgh Medical Center
and Magee Women's Hospital of Pittsburgh

PUBLICATIONS

REFEREED ARTICLES

1. Densen P, Greene D, Moskowitz R, Sack J, Scheff D, Taw R, Trump DL, Zawatshy L, Starfield B.
Primary medical care of an urban population: a survey of present and potential utilization. J Med Educ
43:1244, 1968.
2. Trump DL, Hochberg M. Bromide intoxication. The Johns Hopkins Med J. 138-139, 1976.
3. Egorin M, Trump DL, Wainwright CW. Rheumatoid arthritis and quinacrine ochronosis. J Am Med
Assoc 236-285, 1976.
4. Trump DL, Livingston JN, Baylin SB. Watery diarrhea syndrome in an adult with ganglioneuroma-
pheochromocytoma: Identification of vasoactive intestinal peptide, calcitonin and catecholamines and

- assessment of their biological activity. *Cancer* 40:1526-1532, 1977.
5. Trump DL, Cowall DE. Acute myelogenous leukemia as a late complication of the multimodality therapy for Hodgkin's disease. *The Johns Hopkins Med J* 141:249-251, 1977.
 6. Trump DL, Fahnestock R, Cloutier CT, Dickman MD. Anaerobic liver abscess and intrahepatic metastases: a case report and review of the literature. *Cancer* 41:682-686, 1978.
 7. Baylin SB, Hsu TH, Steve SA, Kallman CH, Trump DL, Beaven MA. The effects of 1-dopa on *in vitro* and *in vivo* calcitonin release from medullary thyroid carcinoma. *J. Clin Endo Metab* 48:408-414, 1979.
 8. Ettinger DS Vitale PJ, Trump DL. Important clinical pharmacologic considerations in the use of methadone in cancer patients. *Cancer Treat Repts* 63:457-459, 1979.
 9. Trump DL, Mendelsohn G, Baylin SB. Discordance between plasma calcitonin content and tumor cell mass in a patient with advanced medullary thyroid carcinoma: a manifestation of phenotypic heterogeneity within the primary tumor. *New Engl J Med* 301:253-255, 1979.
 10. Trump DL, Mendelsohn G, Shoback D. Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) in Clinical Conferences at the Johns Hopkins Hospital. *The Johns Hopkins Med J* 144:101-106, 1979.
 11. Trump DL, Allen H, Olson J, Wright J, Humphrey RL. Amyloidosis, multiple myeloma and epidermolysis bullosa acquisita: a case report and review of literature. *J Am Med Assoc* 243: 1461-1462, 1980.
 12. Trump DL, Mann RB, Phelps R, Roberts H, Conley DL. Richter's syndrome: The occurrence of diffuse histiocytic lymphoma in patients with chronic lymphocytic leukemia. Report of five new cases and reiew of literature. *Am J Med* 68:539-548, 1980.
 13. Trump DL, Linet M. Lymphoma and cancer of the testis (letter to the editor). *N Engl J Med* 303:1063, 1980.
 14. Marshall E, Farmer E, Trump DL. Cutaneous involvement in malignant histiocytosis. *Arch Derm* 117:278-281, 1981.
 15. Trump DL, Ettinger DS, Feldman MJ, et al. Granulomatous mediastinal lymphadenopathy ("sarcoidosis") – following cytotoxic and radiation therapy of testis cancer. *Arch Int Med* 141:37-38, 1981.
 16. Trump DL. Serious hyponatremia in patients with cancer: management with demeclocycline. *Cancer* 47:2908-2912, 1981.
 17. Trump DL, Ettinger DS, Abeloff MD. Doxorubicin, vincristine and cisdiaminedichloroplatinum (II) therapy in patients with advanced breast cancer. *Med Ped Onc* 9:11-3, 1981.
 18. Ehrlichman RJ, Kauffman SL, Siegelman SS, Trump DL, Walsh PC. Computerized tomography and lymphangiography in staging of testis tumors. *J. Urol* 126:179-181, 1981.
 19. Marshall E, Trump DL. Acquired extrinsic pulmonic stenosis cause by mediastinal tumors. *Cancer* 49:1496-1499, 1981.
 20. Abeloff MD, Trump DL, Baylin SB. Ectopic adenocorticotrophic (CTH) syndrome and small cell carcinoma of the lung – assessment of clinical implications in patients on combination chemotherapy. *Cancer* 48:1082-1087, 1981.
 21. Trump DL. Update on Dx and management of bladder ancer. *Geriatrics* 37(7):87-91, 1982.
 22. Economou JS, Trump DL, Holmes EC, Eggleston JE. Management of primary germ cell tumors of the mediastinum. *J Thorac Cardiovas Surg* 83:643-649, 1982.
 23. Trump DL, Mann RB. Diffuse large cell and undifferentiated lymphomas with prominent mediastinal involvement: a poor prognostic subset of patients with non-Hodgkin's lymphoma. *Cancer* 50:277-282, 1982.
 24. Lippman SM Mendelsohn G, Trump DL, et al. The prognostic and biologic significance of cellular heterogeneity in medullary thyroid cancer. *J Clin Endo Metab* 54:233-240, 1982.
 25. Trump DL, Pavy MD, Staal S. Gynecomastia in adult males following antineoplastic therapy. *Arch Intern Med* 142:511-512, 1982.
 26. Trump DL, Grossman SA, Thompson G, Murray K. Cerebrospinal fluid infections complicating the management of neoplastic meningitis: Clinical features and results of therapy. *Arch Intern Med* 142:583-586, 1982.
 27. Trump DL, Abeloff MD, Hsu TH. Abnormalities of water and cortical metabolism in patients with small cell brochogenic cancer and other neoplasms. *Chest* 81:576-580, 1982.
 28. Markman M, Trump DL. Nephrotoxicity with cisplatin and antihypertensive medications. *Ann Int Med* 96:257, 1982.

29. Trump DL, Grossman SA, Thompson G, Murry K., Wharam M. Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate. *Cancer Treat Rept* 66:1549-1551, 1982.
30. Grossman SA, Trump DL, Chen DCP, Thompson G, Carmargo E. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis: An evaluation using 111 Indium-DTPA ventriculography. *Amer J Med* 73:641-647, 1982.
31. Trump DL, Anderson SA. Painful gynecomastia following cytotoxic therapy for testis cancer: A potentially favorable prognostic sign? *J Clin Oncol* 1:416-420, 1982.
32. Trump DL. Current concepts in the natural history and therapy of bladder cancer. *Geriatrics* 37:87-91, (1982).
33. Trump DL, Loening S, Ahmed SW, Wajzman Z, Phase II study of m-AMSA in previously treated patients with advanced transitional cell carcinoma of the urothelium: A NBCCGA study. *Cancer Treat Rept* 67:845-846, 1983.
34. Haupt HM, Mann DB, Trump DL, Abeloff MD. Metastatic carcinoma involving the testis: Clinical and pathologic distinction from primary testicular neoplasms. *Cancer* 54:709-417. 1984.
35. Trump DL, Loprinzi CL. A Phase II study of etoposide (VP-16-213) in advanced prostate cancer. *Cancer Treat Rept* 1195-1196, 1984.
36. Block M, Trump DL, Rose DP, et al. Aminoglutethimide treatment of Stage D prostate cancer: Clinical and pharmacologic studies. *Cancer Treat Rept* 68:719-722, 1984.
37. Kuebler JP, Hogan TF, Trump DL, Bryan GT. Phase II study of continuous five day vinblastine infusion in renal adenocarcinoma. *Cancer Treat Rept* 68:925-926, 1984.
38. Trump DL, Hortvet L. Etoposide (VP16) and very high dose cisplatin in refractory testis cancer. *Cancer Treat Rept* 69:259-261, 1985.
39. Benson AB, Trump DL, Koeller JM, Egorin MJ, Olman EZ, Witte RS, Davis TE, Tormey DC. A phase I study of vinblastine and verapamil given by concurrent intravenous infusion. *Cancer Treat Rept* 69:795-799, 1985.
40. Grem JL, Burgess J, Trump DL. Clinical features and natural history of intramedullary spinal cord metastasis. *Cancer* 59(9):2305-2314, 1985.
41. Grem JL, Neville AH, Smith S, Gould H, Love RR, Trump DL. Massive skeletal muscle invasion II lymphoma. *Arch Int medicine* 145:1818-1820, 1985.
42. Trump DL, Tutsch KD, Koeller JM, Tormey DC. Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide administered as a 5-day infusion. *Cancer Res* 45(6):2853-2858, 1985.
43. Koontz WW, Heney NM, Solway MS, Kluskens L, Hazra TA, Trump DL Barton B. Mitomycin for patients who have failed thiotepa. *J Urol (suppl)* 26:30-31, 1985.
44. Bensen AB III, Trump DL, Cummings KB, Fischer PH. Modulation of 5-iodo-2'-deoxyuridine metabolism and cytotoxicity in human bladder cancer cells by fluoropyrimidines. *Biochem Phar* 34(21):3925-3931, 1985.
45. Romsaas EP, Malec JF, Trump DL. Psychological profile of patients with testis cancer. *J Psychology Oncol* 3:55-64, 1985.
46. Koeller JM, Trump DL, Tutsch DK, Earhart RH, Davis TE, Tormey DC. Phase I trial of carboplatin (NSC 241240) by bolus intravenous injection. *Cancer* 57:222-225, 1986.
47. Change AYC, Kuebler PJ, Tomrey DC, Pandya KJ, Borden EC, Davis TE, Trump DL, Anderson S. Phase II evaluation of combination of MVP in advanced non-small cell lung cancer. *Cancer* 57:54-59, 1986.
48. Romsaas EP, Malec JF, Javenkoski BR, Trump DL, Wolberg WH. Psychological distress among woemn with breast problems. *Cancer* 57(4):890-895, 1986.
49. Kohler PC, Trump DL. Ectopic hormone syndromes, *Cancer Invest* 4(6):543-54, 1986.
50. Grem JL, Robins HI, Wilson KS, Gilchrist K, Trump DL. Metastatic Leydig cell tumor of the testis: Report of three cases treated with lonidaminie and review of the literature. *Cancer* 58:2116, 1986.
51. Grem JL, Trump DL. Reversible increase in serum AFP content associated with hepatic dysfunction during chemotherapy for seminoma. *J Clin Oncol* 4:41, 1986.
52. Glover D, Trump DL, Kvols L, Elson P, Vogl S. Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma. *Int J Radiat Oncol Phys* 12:1405-1408, 1986.
53. Kohler P, Trump DL. Ectopic hormone syndromes. *Cancer Investigation* 4(6):105-122 (1986).
54. Trump DL, Elson PR, Borden EC, Harris JE, Tuttle RL, Whisnant JK, Oken MM, Carignan JR, Ruckdeschel JC, Davis TE. High dose lymphoblastoid interferon in advanced renal cell carcinoma:

- An ECOG pilot study. *Cancer Treatment Rept* 71:165-169, 1987.
55. Trump DL, Tutsch KD, Willson JKV, Simon KJ, Alberti D, Grem J, Tormey DC, Storer B. Platinum Analogue Combination Chemotherapy: Cisplatin and carboplatin—A phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. *J Clin Oncol* 5:1281-1289, 1987.
 56. Wolberg WH, Tanner MA, Romsaas EP, Trump DL, Malec JF. Factors influencing options in primary breast cancer treatment. *J Clin Oncol* 5:68-74, 1987.
 57. Trump DL, Elson P, Bordovsky H. Carboplatin in advanced refractory germ cell neoplasms: a phase II eastern cooperative oncology group study. *Cancer Treat Rept.* 71:989-990, 1987.
 58. Ahmann FR, Citrin DL, deHann HA, Guinan P, Jordan VC Kreis W, Scott M, Trump, DL. Zoladex: A sustained release, monthly luteinizing hormone releasing hormone analogue for the treatment of advanced prostate cancer. *J Clin Oncol* 5:912-917, 1987.
 59. Grem JL, Tutsch KD, Simon KJ, Alberti DB, Willson JKV, Tomrey DC, Swaminathan S, Trump DL. Phase I study of taxol administered as a short intravenous infusion for 5 days. *Cancer Treat Rept*, 71:1179-1184, 1987.
 60. Trump DL, Tutsch KD, Willson JKV, Remick S, Simon K, Alberti D, Grem J, Koeller J, Tormey D. Phase I and pharmacokinetic trial of acodazole, an imidazolequinoline with cardiac electrophysiologic effects. *Cancer Res* 47:3895-3900, 1987.
 61. Elson PJ, Earhart RH, Kvols LK, Speigel R, Keller AM, Kies MS, Davis TE, Stevens C, Gumas L, Trump DL. Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma. *Cancer Treat Rept* 71:331-332, 1987.
 62. Remick SC, Grem JL, Fischer PH, Tutsch KD, Alberti DB, Simon K, Trump DL: Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. *Cancer Res* 28:227, 1987.
 63. Havlin KA, Trump DL. Aminogluthethimide: theoretical considerations and clinical results in advanced prostate cancer. *Cancer Treat Res* 39:83-96, 1988.
 64. Malec JF, Wolberg WH, Tanner MA, Romsaas EP, Trump DL. Million clinical multiaxial inventory (MCMi) findings among breast clinic patients following initial evaluation and at 4-8 month follow-up. *J Clin Psych* 44:175-180, 1988.
 65. Willson JKV, Tutsch KD, Fischer PF, Trump DL. A phase I trial of acivicin and dipyridamole – clinical and pharmacologic results. *Cancer* 48:5585-5590, 1988.
 66. Fischer PF, Willson JV, Risueno C, Tutsch KD, Bruggink J, Trump DL. Biochemical assessment of the effects of acivicin and dipyridamole given as a continuous 72-hour intravenous infusion. *Cancer Res* 48:5591-5596, 1988.
 67. Mulcahy RT, Trump DL. Clinical chemosensitization by misonidazole and related compounds. *J Clin Oncol* 6:569-573, 1988.
 68. Hansen RM, Banerjee TK, Davis HL, Zaentz SD, Schiferl EA, Ousley JL, Pogodzinski AE, Trump DL. Sequential 5-fluorouracil, methotrexate, and calcium leucovorin in metastatic colorectal cancer. *Wisconsin Medical Journal* 87:20-23, 1988.
 69. Trump DL, Bartel E, Pozniak M. Nodular pneumonitis after chemotherapy for germ cell tumors. *Ann Int Med* 109: 431-432, 1988.
 70. Heney NM, Koontz, WW, Barton B, Soloway M, Trump DL, Hazra T, Weintein RS. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and T1S transitional cell carcinoma of the bladder: a phase III prospective randomized study. *J Urology* 140:1390-1393, 1988.
 71. Elson PJ, Kvols LK, Vogel SE, Glover DJ, Hahn RG, Trump DL, Carbone PP, Earle JD, Davis TE. Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma. *Investigational New Drugs* 6:97-103, 1988.
 72. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. *Cancer Res* 48:7310-7313, 1988.
 73. Willson JKV, Fischer PH, Tutsch , Alberti D, Simon K, Hamilton RD, Bruggink J, Koeller JM, Tormey DC, Earhart RH, Ranhosky A, Trump DL. Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. *Cancer Res* 48:5585-5590, 1988.
 74. Schiller JH, Ritch PS, Storer B, Trump DL. A pilot study of short-course high-dose cytosine arabinoside, etoposide, and cisplatin in refractory, aggressive-histology, non-Hodgkin's lymphomas, *Am J Clin Onc* 12:502-506, 1989.

75. Schiller JH, Rozenthal J, Tutsch KD, Trump DL. Inadvertent administration of 480 mg/m² of cisplatin. *Amer J Med* 86:624-625, 1989.
76. Trump DL, Havlin KH, Messing EM, Cummings KB, Lange PH, Jordan VC. High-dose ketoconazole in advanced hormone refractory prostate cancer: endocrinologic and clinical effects. *J Clin Oncol* 7:1093-1098, 1989.
77. Willson JKV, Fischer PH, Remick SC, Tutsch KD, Grem JL, Nieting L, Alberti D, Bruggink J, Trump DL. Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans. *Cancer Res* 49:1866-1870, 1989.
78. Rozenthal JM, Robins HI, Finlay J, Healey B, Levin AB, Steeves RA, Kohler PC, Schutta HS, Trump DL. "Eight-drugs-in-one-day" chemotherapy in postirradiated adult patients with malignant gliomas. *Med Pediatr Oncol* 17(6):471-476, 1989.
79. Remick SC, Benson AB III, Weese JL, Willson JKV, Ramirez G, Wirtanen GW, Alberti DB, Nieting LM, Tutsch KD, Fischer PH, Trump DL. Phase I trial of hepatic artery infusion of 5-Iodo-2'-deoxyuridine and 5-fluorouracil in patients with advanced hepatic malignancy: biochemically based combination chemotherapy. *Cancer Res* 49:6437-6442, 1989.
80. Trump DL, Elson P. Evaluation of carboplatin (NSC 241240) in patients with recurrent or metastatic renal cell carcinoma. *Inv New Drugs* 8:201-203, 1990.
81. Trump DL, Ravdin PM, Magers CF, Borden EC, Whisnant JK. Interferon alpha and continuous infusion vinblastine for treatment in advanced renal cell carcinoma. *J Biol Resp modifiers* 9:108-111, 1990.
82. Trump DL, Marsh JC, Kvols LK, Citrin D, Davis TE. A phase II trial of carboplatin in advanced prostate cancer refractory to hormonal therapy. *Inv New Drugs* 8:S91-S94, 1990.
83. Dreicer R, Trump DL, Messing E, et al. Perioperative methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: an Eastern Cooperative Oncology Group pilot study. *J Uro* 144: 1123-1127, 1990.
84. Trump DL, Madajewics S, Elson P, et al. Randomized Phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. *J Urol* 144:1119-1122, 1990.
85. Malec JF, Romsaas EP, Messing EM, Cummings KC, Trump DL. Psychological and mood disturbance associated with the diagnosis and treatment of testis cancer and other malignancies. *J Clin Psychology* 46:551-557, 1990.
86. Borden EC, Rinehart JJ, Storer BE, Trump DL, Paulnock DFM, Teitelbaum AP. Biological and clinical effects of interferon-beta ser at two doses. *J Interferon Res* 10:559-570, 1990.
87. Goldstein D, Chevart B, Trump DL, Shiraki M, Comis RL, Tormey DC, Harris JE, Borden EC. Phase II trial of carboplatin in soft-tissue sarcoma. *Am J Clin Oncol* 13(5):420-423, 1990.
88. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Van Echo DA, Von Hoff DD, Leyland-Jones B: Hypersensitivity reactions from taxol. *J Clin Onc* 8:1263-1268, 1990.
89. Einzig AI, Hochster H, Wiernik PH, Trump DL, Dutcher JP, Garowski E, Sasloff J, Smith TJ. A phase II study of taxol in patients with malignant melanoma. *Invest New Drugs*, 9(1):59-64, 1991.
90. Pozniak MA, Bable SG, Trump DL. Complications of hepatic arterial infusion chemotherapy. *Radiographics* 11:67-79, 1991.
91. Bailey H, Mulcahy RT, Tutsch KD, Rozenthal JM, Alberti D, Arzoomanian RZ, Tomes MB, Trump DL, Wilding G. A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection. *Can Res* 51:1059-1358, 1991.
92. Schiller JH, Storer BE, Witt PL, Alberti D, Tombes MB, Arzoomanian R, Proctor RA, McCarthy D, Brown RR, Voss SD, Remick SC, Grem JL, Borden EC, Trump DL. Biological and clinical effects of intravenous tumor necrosis factor-administered three times weekly. *Cancer Res* 51:1651-1658, 1991.
93. Neidhart JA, Anderson SA, Harris JE, Rinehart JJ, Laszlo J, Dexeus FH, Einhorn LH, Trump DL, Pasquale WB, Tuttle RL, Smalley RV: Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. *J Clin Oncol* 9:832-836, 1991.
94. Grem J, O'Dwyer P, Elson E, Simon N, Trump DL, Frontiera M, Falkson G, Vogl S: Cisplatin, carboplatin and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: An Eastern Cooperative Oncology Group Pilot Study. *J Clin Onc* 9:1973-1800, 1991.
95. Trump DL, Egorin MJ, Forest A, Willson JKV, Remick S, Tutsch KD: Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. *J Clin Oncol* 9:2027-2035, 1991.
96. Schiller JH, Witt PL, Storer B, Alberti D, Tombes MB, Arzoomanian R, Brown RR, Proctor RA, Voss

- Sd, Spriggs DR, Trump DL, Borden EC: Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor. *Cancer* 69:562-571, 1991.
97. Einzig AI, Hochster H, Weirnik PH, Trump DL, Dutcher JP, Barowski E, Sasloff J, Smith TJ. A phase II study of taxol in patients with malignant melanoma. *Invest New Drugs* 9(1):59-64, 1991.
 98. Smith DC, Tucker JA, Trump DL: Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature. *J Clin Onc* 10:499-505, 1992.
 99. Witte RS, Elson P, Bryan GT, Trump DL: Trimetrexate in advanced renal cell carcinoma. *Inv. New Drugs* 10:51-54, 1992.
 100. Witte RS, Walsh C, Fisher H, Okem MM, Reding DJ, Trump DL. Evaluation of deoxycoformycin in patients with advanced renal cell carcinoma. *Investigation New Drugs* 10:49-50, 1992
 101. Smith DC, Vick NA, Trump DL, Friedman HS, Freidman AH, Purvis J, Gauspari A, Schold SC Jr.: Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. *Cancer Chemother Pharmacol*, 30(4):272-276, 1992
 102. Lehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosday MF, Lowe BA, Blemenstein B, Trump DL. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma. *J Clin Onc*, 10:1066-1073, 1992.
 103. Steinberg GD, Trump DL, Cummings KB. Metastatic Bladder Cancer. *Urolog Clin of North AM*, 19:15-12, 1992.
 104. Penta JS, Rosner GL, Trump DL. Choice of starting dose and escalation for phase I studies of antitumor agents. *Cancer Chemotherapy and Pharmacology*, 31:247-250, 1992.
 105. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winter EP, Panella TJ, Jordan VC, Fine RL. High-dose oral tamoxifen, a potential multi-drug resistance-reversal agent: Phase I trial in combination with vinblastin. *J Natl Can Inst* 84(23):1811-1816, 1992.
 106. Penta JS, Rosner GL, Trump DL. Choice of starting dose and escalation for phase I studies of antitumor agents. *Cancer Chemother Pharmacol* 31:247-250, 1992.
 107. Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA, Loehrer PJ, Trump DL. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: An Eastern Cooperative Oncology Group protocol. *J Clin Oncol*: 10(4):558-563, 1992.
 108. Panella TJ, Smith DC, Schold SC, Rogers MP, Winer EP, Fine RL, Crawford J, Herndon JE 2d, Trump DL. Modulation of O6-alkylguanine-DN alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trials. *Cancer Res* 52(9):2456-2459, 1992.
 109. Trump DL. Prostate Cancer: How to screen. *Consultants* 32:27-36 (1992).
 110. Roth BJ, Elson P, Sledge G, Einhorn LH, Trump DL. 5-Azacytidine (NSC 102816) in refractory germ cell tumors: A phase II trial of the Eastern Cooperative Oncology Group. *Invest New Drugs* 11 (2-3):201-202, 1993.
 111. Smith DC, Duncan IJ, Eogrin JJ, Ambinder RM, Zuhowski EG, Kreis W, Ellis RG, Trump DL. A phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer: *Cancer Chemother Pharmacol* 31:363-368, 1993.
 112. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. *J Clin Onc*, 11:3 561-569, 1993.
 113. Antman K, Crowley J, Balcerzak P, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, Doroshow JH, Aisner J, Pugh RP, Weiss RB, Cooper BA, Clamond GH, Baker LH. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. *J Clin Oncol* 11:1276-1285, 1993.
 114. Canada A, Herman L, Kidd K, Robertson C, Trump DL. Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line. *Cancer Chemother Pharmacol* 32(1):73-77, 1993.
 115. Nolten WE, Goldstein D, Lindstrom M, McKenna MV, Carlson IH, Trump DL, Schiller J, Borden EC, Ehrlich EN. Effects of cytokines on the pituitary-adrenal axis in cancer patients. *J Interferon Res*. 13(5):349-357, 1993.
 116. Smith DC, Vaughan WP, Gwilt PR, Trump DL. A phase I trial of high-dose continuous-infusion hydroxyurea. *Cancer Chemother Pharmacol* 33(2): 139-143, 1993.
 117. Taylor CD, Elson P, Trump DL, Importance of continued testicular suppression in hormone refractory prostate cancer. *J Clin Oncol* 11:2176-2172, 1993.
 118. Smith DC, Jodrell DI, Eogrin MJ, Ambinder RM, Zuhowski EG, Kreis W, Ellis PG, Trump DL.

- Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer. *Cancer Chemother Pharmacol*. 31(5):363-368, 1993.
119. Fine RL, Sachs CW, Albers ME, Safa A, Rao US, Scarborough G, Burchette J, Jordan C, Trump DL. Inhibition of multidrug resistance in human cancer cells by tamoxifen: Laboratory to clinical studies. *Journal of Biological Chemistry*, 1993.
 120. Petros WP, Chaney SG, Smith DC, Fangmeier J, Sakata M, Brown TD, Trump DL. Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial. *Cancer Chemother Pharmacol* 33:347-54, 1994.
 121. Rowinsky EK, Noe DA, Lucas VS, Trump DL, Winer EP, Wargin WA, Hohneker JA, Lebejko B, Sartorius SE, Ettinger DS, Donehower RC. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine (navelbine) in patients with solid tumors. *J Clin Oncol* 12:1754-1763, 1994.
 122. Witte RS, Yeap BY, Trump DL. Trimetrexate in advanced hormone-refractory prostate cancer: An ECOG phase II trial. *Investigational New Drugs* 12:255-258, 1994.
 123. Witte RS, Elson P, Khandakar J. Trump DL. An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. *Cancer*. 73(3):688-691, 1994.
 124. Chan KK, Hong PS, Tutsch K, Trump DL. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508. *Cancer Research* 54:6421-6429, 1994.
 125. Trump DL, Hathorn JA, Grochow LB, Spriggs D, Eble ML, Hohneker JA. Phase II evaluation of the AMAP, 773U82 mesylate, in pancreatic cancer. *Invest. New Drugs* 12(4):273-276, 1994.
 126. Trump DL. Retinoids in bladder, testis and prostate cancer: epidemiologic, pre-clinical and clinical observations. *Leukemia* 8. Suppl. 3:S50-54, 1994.
 127. Chang AY, Tu ZN, Bryan GR, Kirkwood JM, Oken MM, Trump DL. Phase II study of echinomycin in the treatment of renal cell carcinoma —ECOG study E2885. *Inv. New Drugs*. 12(2):151-153, 1994.
 128. Loehrer PJ Sr, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. *J Clin Oncol* 13(2):470-476, 1995.
 129. Smith DC, Trump DL. A phase I trial of high-dose oral tamoxifen and CHOPE. *Cancer Chemother Pharmacol* 36:65-68, 1995.
 130. Tracewell WG, Trump DL, Vaughan WP, Smith DC, Witel PR. Population pharmacokinetics of hydroxyurea in cancer patients. *Cancer Chemother Pharmacol* 35:417-422, 1995.
 131. McElwain, MC, Dettlebach MA, Modzelewski RA, Russell DM, Uskokovic MR, Smith DC, Trump DL, Johnson CS. Antiproliferation effects *in vitro* and *in vivo* of 1,25-dihydroxyvitamin D₃ and a vitamin D₃ analogue in squamous cell carcinoma model system. *Mol. Cell Diff.* 3(1):31-50, 1995.
 132. Lerner SE, Tsai H, Flanigan RC, Trump DL, Fleischmann J. Renal cell carcinoma: considerations of nephron-sparing surgery. *Urology*, 45(4):574-577, 1995.
 133. Bahnon RR, Smith D, Trump DL. Adjuvant chemotherapy for bladder cancer. Standard of care or unproven therapy? *Surg Oncol Clin N Am* 4(2):287, 1995.
 134. Osborn J, Getzenberg RH, Trump DL. Spinal cord compression in prostate cancer: *J. Neurooncol*. 23(2):135-147, 1995.
 135. Witte RS, Leong T, Ernstoff MS, Krigel RL, Oken MM, Harris J, Tormey DC, Trump DL. A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma. *Invest New Drugs* 13:241-247, 1995.
 136. Seidmon EJ, Trump DL, Kreis W, Hall SW, Kurman MR, Ouyang SP, Wu J, Kremer AB. Phase I/II Dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate. *Ann Surg Oncol*, 2(6):550-556, 1995.
 137. Osborn JL, Schwartz GG, Smith DC, Bahnon R, Day R, Trump DL. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. *Urol Oncol* 1:195-198, 1995.
 138. Witte RS, Hsieh P, Elson P, Oken MM, Trump DL. A phase II trial of amonafide, caracemide, and homoharringtonin in the treatment of patients with advanced renal cell cancer. *Invest New Drugs*, 14(4):409-413, 1996.
 139. Smith DC, Gerson SL, Liu L, Donnelly S, Day R, Trump DL, Kirkwood JM. Carmustine and streptozocin in refractory melanoma: Potentiation of toxicity by modulation of O⁶-Alkylguanine-DNA-Alkyltransferase. *Clin Cancer Res* 2(7):1129-1134, 1996.
 140. Canada AT, Robertson KM, Vessalla RL, Trump DL, Robertson CN, Fine RL. Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues. *Biochem Pharmacol* 51:1:87-90, 1996.
 141. Loprinzi CL, Messing EM, O'Fallon JR, Poon MA, Love RR, Quella SK, Trump DL, Morton FR,

- Novotny P. Toxicity evaluation of difluoromethylornithine (DFMO): Doses for chemoprevention trials. *Cancer Epidemiol Biomarkers Prev* 5:371-374, 1996.
142. Chang B, Yeap TD, Davis T, Blum R, Hahn R, Khanno O, Fisher H, Rosenthal J, Witte R, Schinella R, Trump DL. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. *J Clin Oncol*. 14:2250-2257, 1996.
 143. Witte RS, Hsieh P, Elson P, Oken MM, Trump DL. A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer. *Investigational New Drugs* 14:409-413, 1996.
 144. Hadeed V, Trump DL. Prostate Cancer; update on the why, when and how of screening. *Consultant* 36: 2036-2047 (1996).
 145. Osborn JL, Smith DC, Trump DL. Megestrol acetate in the treatment of hormone refractory prostate cancer. *Am J Clin Oncol* 20(3):308-310, 1997.
 146. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ, Trump DL. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methorexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. *J Clin Oncol* 15:2564-2569, 1997.
 147. Trump DL, Smith DC, Stiff D, Adedoyin A, Day R, Bahnson RR, Hofacker J, Branch RA. A Phase II trial of all-trans-retinoic acid in hormone refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. *Cancer Chemother Pharmacol* 39(4):349-356, 1997.
 148. Samuels BL, Hollis DR, Rosner GL, Trump DL, Shapiro CL, Vogelzang NJ, Schilsky RL. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or Tamoxifen: A CALGB study. *Clin Cancer Research* 3(11):1977-1984, 1997.
 149. Yu WD, Chang MJ, Trump DL, Johnson CS. Interleukin -1 α synergistic *in vivo* enhancement of cyclophosphamide-and carboplatin-mediated anti-tumor activity. *Cancer Immunol Immunother* 44:316-322, 1997.
 150. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. *Cancer Res*, 57:3759-3764, 1997.
 151. Getzenberg RH, Light BW, Lopco PE, Konety BR, Nangia AK, Acierno JS, Chir R, Shrin Z, Day RS, Trump DL, Johnson CS. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. *Urology* 50(6):999-1006, 1997.
 152. Yu WD, McElwain MC, Modzelewski RA, Russell DM, Smith DC, Trump DL, and Johnson CS. Enhancement of 1,25-dihydroxyvitamin D₃-mediated anti-tumor activity with dexamethasone. *J Natl Cancer Inst*, 90:134-141, 1998.
 153. Adedoyin A, Stiff DD, Smith DC, Romkes M, Bahnson RC, Day R, Hofacker J, Branch RA, Trump DL. All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes. *Cancer Chemother Pharmacol*, 41(2):133-139, 1998.
 154. Hadeed V, Trump DL, Mies C. Electronic cancer manchausen syndrome [letter] *Ann Intern Med* 129(1):73, 1998.
 155. Berlin JD, Propert KJ, Trump D, Wilding G, Hudes G, Glick J, Burch P, Keller A, Loehrer P. 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889). *Am J Clin Oncol*. 21(2):171-6, 1998.
 156. Bublely GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Friedlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen independent prostate cancer: Recommendations from the PSA working group. *J Clin Oncol* 17(11) 3461-3467, 1999.
 157. Messing EM, Manola J, Sarodsy M, Wilding G, Crawford ED, Trump DL. Immediate Hormone therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. *N Engl J Med* 341:1781-1788, 1999.
 158. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Mars V, Trump DL, Winer EP, Vogelzang NJ. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and Leukemia Group B study. *J Clin Oncol* 17(8):2506-2513, 1999.
 159. Woolley PV, Frieha FS, Smith DC, Carlson L, Hofacker J, Quinn N, Grove W, Trump DL. A phase II trial of CI-958 in patients with hormone-refractory prostate cancer. *Cancer Chemother Pharmacol* 44:511-517, 1999.
 160. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A phase I trial of calcitriol

- (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. *Clin Cancer Res* 5:1339-1345, 1999.
161. Konety BR, Johnson CS, Trump DL, Getzenberg RH. Vitamin D in the prevention and treatment of prostate cancer. *Semin Urol Oncology* 17(2):77-84, 1999.
 162. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1,25-Dihydroxycholecalciferol (1,25-D₃) inhibits the growth of Squamous cell carcinoma and down-modulates p21^{waf1/cip1} in vitro and in vivo. *Cancer Res* 59:2644-2649, 1999.
 163. Zeng Q, Smith DC, Suscovich TJ, Gooding WE, Trump DL, Grandis JR. Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole. *Clin Cancer Res* 6(6):2245-51, 2000.
 164. McGuire TF, Trump DL, Johnson CS. Vitamin D₃-induced apoptosis of murine squamous cell carcinoma cells: Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. *J Biologic Chemistry* 276(28):26365-26373, 2001.
 165. Obasaju C, Manola J, Hudes GR, Khandekar JD, Citrin DL, Carbone P, Trump DL. Phase II evaluation of menogaril in advanced prostate cancer: An Eastern Cooperative Oncology Group Study PA885. *Am J Clin Oncol* 24(2):150-154, 2001.
 166. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. *Clin Cancer Res* 7(4):1043-1051, 2001.
 167. Konety, BR, Lavelle JP, Pirtskalaishvili G, Dhir R, Meyers SA, Nguyen TST, Hershberger P, Shurin MR, Johnson CS, Trump DL, Ziedel ML, Getzenberg RH. Effects of Vitamin D (Calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. *J Urol* 165:253-258, 2001.
 168. Bernardi RJ, Trump DL, Yu WD, McGuire TF, Hershberger PA, Johnson CS. Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. *Clin Cancer Res* 7(12):4164-4173, 2001.
 169. Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA, Ferrell RE. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. *Clin Cancer Res* 7(10):3092-3096, 2001.
 170. Winters SJ, Brufsky A, Weissfeld J, Trump DL, Dyky MA, Hadeed V. Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men. *Metabolism* 50(10):1242-1247, 2001.
 171. Trump DL, Waldstreicher JA, Kolvenbag G, Wissel PS, Neubauer BL. Androgen antagonists: Potential role in prostate cancer prevention. *Urology* 57(4 Suppl 1):64-67, 2001.
 172. Pirtskhalaishvili G, Shurin GV, Esche C, Trump DL, Shurin MR. TNF-alpha protects dendritic cells from prostate cancer-induced apoptosis. *Prostate Cancer Prostatic Dis* 4:221-227, 2001.
 173. Johnson CS, Hershberger PA, Bernardi RJ, McGuire TF, Trump DL. Vitamin D receptor: A potential target for intervention. *Urology* 60 (Suppl 1), 123-131, 2002.
 174. Matin K, Egorin MJ, Ballesteros MF, Smith DC, Lembersky B, Day RS, Johnson CS, Trump DL. Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate. *Cancer Chemother Pharmacol* 50:179-185, 2002.
 175. Bunker CH, Patrick AL, Konety BR, Dhir R, Brufsky AM, Vivas CA, Becich MJ, Trump DL, Kuller LH. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. *Cancer Epidemiol Biomarkers Prev* 11:726-729, 2002.
 176. Fakhri M, Johnson CS, Trump DL. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. *Urology* 60(4):553-561, 2002.
 177. Ahmed S, Johnson CS, Rueger RM, Trump DL. Calcitriol (1,25 dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. *J Urol* 168:756-761, 2002.
 178. Johnson CS, Hershberger PA, Trump DL. Vitamin D-related therapies in prostate cancer. *Cancer Metast Rev* 21:147-158, 2002.
 179. Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL. Pharmacokinetics of high-dose oral calcitriol: results from a phase I trial of calcitriol and paclitaxel. *Clin Pharmacol Ther* 72(6):648-659, 2002.
 180. Ramanathan RK, Potter DM, Belani CP, Jacobs SA, Gravenstein S, Lim F, Kim H, Savona S, Evans T, Buchbarker D, Simon MB, Depee JK, Trump DL. Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients. *J Clin Oncol* 20:4313-4318, 2002.

181. Logan T, Jadali F, Egorin M, Mintun M, Sashin D, Gooding WE, Choi Y, Bishop H, Trump DL, Gardner D, Kirkwood J, Vlock D, Johnson C. Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial. *Cancer Chemother Pharmacol* 50(6):433-444, 2002.
182. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative effects of 1 α ,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. *Endocrinology* 143(7):2508-2514, 2002.
183. Hershberger PA, McGuire T F, Yu WD, Zuhowski EG, Schellens JH, Egorin MJ, Trump DL, Johnson CS. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. *Mol Cancer Therapeutics* 1(10):821-829, 2002.
184. Ahmed S, Trump DL. The case for early androgen deprivation: the data should not be ignored. (Review) *Urologic Oncology* 7:77-80, 2002.
185. Hinton S, Catalano PJ, Einhorn LH, Nichols CR, Crawford ED, Vogelzang N, Trump D, Loehrer PJ. Cisplatin and etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an Intergroup trial. *Cancer* 97:1869-1875, 2003.
186. Xiao D, Srivastava SK, Lew K, Zeng Y, Hershberger P, Johnson CS, Trump DL, Singh VS. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. *Carcinogenesis* 24(5):891-897, 2003.
187. Leaf AN, Propert K, Corcoran C, Catalano P, Trump DL, Harris JE, Davis TE. Phase III study of combined chemohormonal therapy in metastatic prostate cancer. *Med Oncol* 20(2):137-146, 2003.
188. Muindi JR, Wilson JW, Peng Y, Cappozzoli MJ, Johnson CS, Trump, DL. A limited sampling method for the estimation of serum calcitriol area under the curve in cancer patients. *J Clin Pharm* 43:894-900, 2003.
189. Srivastava SK, Xiao D, Lew KL, Hershberger P, Kokkinakis DM, Johnson CS, Trump DL, Singh SV. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo. *Carcinogenesis* 24:1665-1670, 2003.
190. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ; Trump DL, deVere White RW, Sarosdy MF, Wood DP, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N Engl J Med* 349 (9):859-866, 2003.
191. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group Intergroup trial. *J Clin Oncol* 21(7):1214-1233, 2003.
192. Patel A, Coates P, Nelson JB, Trump DL, Resnick NM, Greenspan SL. Does bone mineral density and knowledge influence health-related behaviors of elderly men at risk for osteoporosis? *J Clin Densitometry* 6:323-329, 2003.
193. Trump DL, Lau Y-K. Chemotherapy of Prostate Cancer: Present and Future. *Current Urology Reports* 4:229-232 (2003).
194. Hoffman LJ, Bunker CH, Pellett PE, Trump DL, Patrick AL, Dollard SC, Keenan HA, Jenkins FJ. Elevated seroprevalence of human *herpesvirus 8* among men with prostate cancer. *J Infect Dis* 189:15-20, 2004.
195. Trump DL. Hospice benefits and Phase I cancer trials. Letter to the Editor. *Annals of Internal Medicine* 140:70, 2004.
196. Muindi JR, Modzelewski RA, Peng Y, Trump DL, Johnson CS. Pharmacokinetics of 1 α ,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. *Oncology* 66:62-66, 2004.
197. Xiao D, Johnson CS, Trump DL, Singh SV. Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G₂/M phase cell cycle arrest in PC-3 human prostate cancer cells. *Mol Cancer Ther* 3(5):567-575, 2004.
198. Lee SO, Lou W, Johnson CS, Trump DL, Gao AC. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. *Prostate* 60(3):178-186, 2004.
199. Lee SO, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL, Gao AC. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. *Prostate* 60(4):303-309, 2004.
200. Jung LL, Ramanathan RK, Egorin MJ, Jin R, Belani CP, Potter DM, Strychor S, Trump DL, Walko C,

- Fakih M, Zamboni WC. Pharmacokinetic studies of 9-nitrocarnitrothecin on intermittent and continuous schedules of administration in patients with solid tumors. *Cancer Chemother Pharmacol* 54(6):487-496, 2004.
201. Zamboni WC, Jung LL, Egorin MJ, Potter DM, Friedland DM, Belani CP, Agarwala SS, Wong MM, Fakih M, Trump DL, Jin R, Strychor S, Vozniak M, Troetschel M, Ramanathan RK. Phase I and pharmacologic study of intermittently administered 9-nitrocarnitrothecin in patients with advanced solid tumors. *Clin Cancer Res* 10(15):5058-5064, 2004.
 202. Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD, Johnson CS. Antitumor activity of calcitriol: pre-clinical and clinical studies. *J Steroid Biochem Mol Biol* 89-90(1-5):519-526, 2004.
 203. Xiao D, Choi S, Johnson DE, Vogel VG, Johnson CS, Trump DL, Lee YJ, Singh SV. Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. *Oncogene* 22:23(33):5594-5606, 2004.
 204. Chen X, Bies RR, Ramanathan RK, Zuhowski EG, Trump DL, Egorin MJ. Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies. *Cancer Chemother Pharmacol* 55(3):237-243, 2005.
 205. Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump DL, Gao AC. Interleukin-6 polymorphism is associated with more aggressive prostate cancer. *J Urol* 174(2):753-756, 2005.
 206. Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ. Phase I pharmacokinetic-pharmacodynamic study of (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. *Clin Cancer Res* 11(9):3385-3391, 2005.
 207. Singh SV, Srivastava SK, Choi S, Lew KL, Antosiewicz J, Xiao D, Zeng Y, Watkins SC, Johnson CS, Trump DL, Lee YJ, Xiao H, Herman-Antosiewicz A. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. *J Biol Chem* 280(20):19911-19924, 2005.
 208. Muindi JR, Potter DM, Peng Y, Johnson CS, Trump DL. Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation. *Cancer Chemother Pharmacol* 56:492-496, 2005.
 209. Fakih MG, Creaven PJ, Ramnath N, Trump D, Javle M, Strychor S, Repinski TV, Zamboni BA, Schwarz JK, French RA, Zamboni WC. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. *Clin Cancer Res* 11(16):5942-5949, 2005.
 210. Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump DL, Gao AC. Interleukin-6 polymorphism is associated with more aggressive prostate cancer. *J Urol* 174(2):753-756, 2005.
 211. Beer TM, Javle M, Lam GN, Henner WD, Wong A, Trump DL. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. *Clin Cancer Res* 11(21):7794-7799, 2005.
 212. Ramanathan RK, Fakih M, Mani S, Deutsch M, Perez RP, Ritter MA, Eiseman JL, Ivy SP, Trump DL, Belani CP, Parise RA, Potter DM, Egorin MJ. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. *Cancer Chemother Pharmacol* 57(4):465-474, 2006.
 213. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. *J Clin Endocrinology & Metabolism* 90(12):6410-6417, 2005.
 214. Lee SO, Chun JY, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). *Prostate* 66(10):1070-1075, 2006.
 215. Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, Gao AC. Stat3 activation of NF- κ B p100 processing involves CBP/p300-mediated acetylation. *Proc Natl Acad Sci USA* 103(19):7264-7269, 2006.
 216. Johnson CS, Muindi JR, Hershberger PA, Trump DL. The Antitumor Efficacy of Calcitriol: Preclinical Studies. *Anticancer Res* 26:2543-2550, 2006.
 217. Ma Y, Yu W-D, Kong R-X, Trump DL, Johnson CS. Role of Nongenomic Activation of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase/Extracellular Signal-

- Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase ½ Pathway in 1,25D3-Mediated Apoptosis in Squamous Cell Carcinoma Cells. *Cancer Res* 66(16):8131-8138, 2006.
218. Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Phase II trial of high dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen independent prostate cancer. *Cancer* 106(10):2136-42, 2006.
 219. Trump DL, Muindi J, Fakhri M, Yu W-D, Johnson CS. Vitamin D compounds: clinical development as cancer therapy and prevention agents. *Anti Cancer Res* 26(4A):2552-2556, 2006.
 220. Johnson CS, Muindi JR, Hershberger PA, Trump DL. The Antitumor Efficacy of Calcitriol: Preclinical Studies. *Anticancer Res* 26:2543-2549, 2006.
 221. Chung I, Wong MK, Flynn G, Yu WD, Johnson CS, Trump DL. Differential anti-proliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. *Cancer Res* 66(17):8565-8573, 2006.
 222. Trump DL, Johnson CS. 2006 Vitamin D: More Than a Hormone – More Than a Calcium and Bone Thing. *Prostate Cancer Communication Newsletter* 22, 4, December 2006.
 223. Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. *Clin Cancer Res*.11: 7794-7799, 2007.
 224. G. Flynn, I. Chung, W.D. Yu, M. Romano, R.A. Modzelewski, C.S. Johnson, D.L. Trump. Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis. *Oncology* 70:447-457, 2006.
 225. M.G. Fakhri, D.L. Trump, J.R. Muindi, J. Black, P.J. Creaven, J. Schwartz, M. Brattain, R.J. Bernardi, A. Hutson, R. French, C.S. Johnson. A Phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. *Clin Cancer Res*. 2007 13: 1216-1223.
 226. Ames JT, Bielwaska A, Hannun Y, Johnson CS, Trump DL. Ceramide analogs prevent growth and cause apoptosis in human prostate cancer. (submitted).
 227. Zmuda JM, Modugno F, Weissfeld JL, Cauley JA, Trump DL, Moffett SP, Ferrell, RE. Peroxisome proliferator-activated receptor-γ polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction. *Oncology* 70 (3):185-189, 2006.
 228. Miller K, Wilding G, Trump D, Trachtenberg J, Tannock I, Raabe N. A phase I/II trial of gefitinib in combination with mitoxantrone and prednisone in patients with hormone-refractory prostate cancer. *European Urology* (submitted).
 229. Wilding G, Soulie P, Trump D, Das-Gupta, A, Small E. Results from a pilot trial of gefitinib (IRESSA) in combination with docetaxel and estramustine in patients with hormone-refractory prostate cancer. *Cancer* (submitted).
 230. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di Sant'Agnese PA, Trump D. Immediate vs delayed androgen deprivation therapy in patients with node positive prostate cancer who had undergone radical prostatectomy + pelvic lymphadenectomy: results of central pathology review. (submitted).
 231. Alagbala AA, Johnson CS, Trump DL, Posner GH, Foster BA. Antitumor effects of two less-calcemic vitamin D analogs (paricalcitol and QW-1624F₂-2) in squamous cell carcinoma cells. *Oncology* 2006;70:483-492.
 232. J.R. Muindi, Y. Peng, J.W. Wilson, M.J. Cappozzoli, Y.M. Cannon, C.S. Johnson, R.A. Branch and D.L. Trump. Monocyte fructose 1,6-bisphosphatase activity: a sensitive measure of calcitriol status and effects in cancer patients. *Cancer Chemother Pharmacol* 59(1):97-104, 2007.
 233. Chung I, Karpf AR, Muindi JR, Conroy JM, Nowak NJ, Johnson CS, Trump DL. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. *J Biol Chem* 2007 Mar 23;282(12):8704-14.
 234. Gupta S, Silliman CG, Trump DL. Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation. *Prostate Cancer Prostatic Dis* 2007;10(4):396-7.
 235. Haussain MH, MacVicar G, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr., Chatta GS, Nanus DM, Glode LM, Trump, DL, Chen H, Smith DC. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma; results of a multicenter phase II National Cancer Institute Trial. *J Clin Oncol* 2007 June 1;25(16):2218-24.
 236. Fakhri MG, Trump DL, Muindi JR, Black JD, Bernardi RJ, Creaven, PJ, Schwartz J, Brattain MG, Hutson A, French R, Johnson CS. A phase I pharmacokinetic and pharmacodynamic study of

- intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. *Clin Cancer Res* 2007 Feb;13(4):1216-23.
237. Hidalgo AA, Paredes R, Garcia VM, Flynn G, Johnson CS, Trump DL, Onate SA. Altered VDR-mediated transcriptional activity in prostate cancer stroma. *J Ster Biochem Mol Biol*. 2007 Mar;103(3-5):731-6.
 238. Alagbala AA, Moser MT, Johnson CS, Trump DL, Foster BA. Characterization of vitamin D insensitive prostate cancer cells. *J Steroid Biochem Mol Bio* 2007 Mar;103(3-5):712-6.
 239. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. *Ann Intern Med*. 2007 Mar 20;146(6):416-24.
 240. Deeb KK, Trump DL, Johnson CS. Vitamin D signaling pathways in cancer; potential for anti-cancer therapeutics. *Nature Rev Cancer*. 2007 Sep;7(9):684-700 Review.
 241. Muindi JR, Nganga A, Engler KL, Coignet LJ, Johnson CS, Trump DL. CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines. *J Steroid Biochem Mol Biol* 2007 Mar;103(3-5):334-7.
 242. Chung I, Yu WD, Karpf AR, Flynn G, Bernardi RJ, Modzelewski RA, Johnson CS, Trump DL. Anti-proliferative effects of calcitriol on endothelial cells derived from two different microenvironments. *J Steroid Biochem Mol Bio* 2007 Mar;103(3-5):768-70.
 243. Rassnick KM, Muindi JR, Johnson CS, Balkman CE, Ramnath N, Yu WD, Engler KL, Page RL, Trump DL. In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. *Cancer Chemother Pharmacol*. 2008 Oct;62(5):881-91.
 244. Ma Y, Yu W-D, Hershberger PA, Flynn G, Kong R-X, Trump DL, and Johnson CS. 1,25D₃ potentiates the anti-tumor activity of cisplatin through increased p73 and enhanced apoptosis in squamous cell carcinoma model system. *Mol Cancer Ther* 2008 Sep;7(9):3047-55.
 245. Chadha MK, Ashraf U, Lawrence D, Tian L, Levine E, Silliman C, Escott P, Payne V, Trump DL. Phase II study of fulvestrant (Faslodex ®) in castration resistant prostate cancer. *Prostate* 2008 Sep 15;68(13):1461-6.
 246. Camoriano M, Kinney SR, Moser MT, Foster BA, Mohler JL, Trump DL, Karpf AR, Smiraglia DJ. Phenotype-specific CpG island methylation events in a murine model of prostate cancer. *Cancer Res* 2008 Jun 1;68(11):4173-82.
 247. Ma Y, Yu WD, Trump DL, Johnson CS. 2009. 125D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. *J Urol* (submitted).
 248. Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S, Resnick NM. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. *J Clin Oncol* 2008 Sep 20;26(27):4426-34.
 249. Lau YK, Chadha MK, Litwin A, Trump DL. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature. *J Hematol Oncol* 2008 Nov 5;1:21.
 250. Fakh MG, Trump DL, Johnson CS, Tian L, Muindi J, Sunga AY. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. *Int J Colorectal Dis* 2009 Feb;24(2):219-24.
 251. Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. *J Urol* 2009 Feb; 181(2):621-6.
 252. Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, Trump DL, Johnson CS. Role of Vitamin D Receptor in the anti-proliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis *in vivo*. *Cancer Res* 2009 Feb; 69(3):967-75.
 253. Trump DL, Chadha M, Sunga AY, Fakh MG, Ashraf U, Silliman CG, Hollis B, Nesline MK, Tian L, Mohler JL, Johnson CS. Vitamin D deficiency and insufficiency among prostate cancer patients. *British J Urol* (in press).
 254. Muindi JR, Johnson CS, Trump DL, Christy R, Engler KL, Fakh MG. A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 2009 April, pp1-8.
 255. Trump DL, Mirand EA. Dr. Roswell Park Physician with a vision. *New York Archives*, Summer 2009.

MANUSCRIPTS SUBMITTED FOR PUBLICATION:

1. Yu W-D, Muindi JR, Ma Y, Engler KL, Kong R-X, Trump DL, and Johnson CS. 2008. CYP24A1 inhibitor enhances the antitumor activity of calcitriol by increased systemic exposure and apoptosis. *Cancer Research* (submitted).

- Ma Y, Yu WD, Trump DL, Johnson CS. 2009. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. J Urol (submitted).

BOOK CHAPTERS

- Trump DL, Baylin SB. Ectopic hormone syndromes. Abeloff MD (Ed). Complications of Cancer: Diagnosis and Management. The Johns Hopkins University Press pp. 211-241, 1979.
- Trump DL. Antineoplastic drugs. Manual of Clinical Pharmacology, Smith, Robertson (Eds.). Baltimore: Williams and Wilkins, pp. 223-247, 1981.
- Trump DL. Pathogenetic mechanisms of bone destruction in cancer. Bone Metastases: Monitoring and Treatment, Stoll BA, Parbhoo S. (Eds.). Raven Press, pp. 39-46, 1983.
- Trump DL. Treatment of bladder cancer. Current Therapy in Hematology-Oncology Vol. 11, Brian MC, Carbone PP (Eds), B.C. Decker, Inc., 1984.
- Trump DL. Complications of cancer chemotherapeutic agents in urologic practice. Urologic Complications, Marshall F (ed.). Yearbook Medical Publishers, 1986.
- Trump DL, Treatment of testicular cancer. Current Therapy in Hematology-Oncology, Vol III, Brain MC, Carbone PP (Eds.), B.C. Decker, Inc., 1987.
- Havlin KA, Trump DL. Aminoglutethimide: theoretical considerations and clinical results in advanced prostate cancer. New Endocrine Therapies for Breast and Prostate Cancer. Osborne, CK. (Ed.). Martinus Nijhoff, 1987.
- Trump DL, Rogers MP. Complications of cancer chemotherapeutic agents in urologic practice. Urologic Complications. Marshall F (ed.). Yearbook Medical Publishers, 1990.
- Trump DL, Elson PA, Madajewicz S. A phase II trial of carboplatin in transitional cell carcinoma. Carboplatin: Current Perspectives and Future Directions. Bunn PA, Canetta R, Ozols RF, Rozenzweig M (Eds.). WB Saunders, 1990.
- Trump DL, Robertson C. Prostate Cancer in Cancer Medicine. Holland J, Frei E (eds). WB Saunders, 1992.
- Trump DL, Smith D. Cancer Chemotherapy in the Elderly in Geriatric Urology text, 1992.
- Trump DL, Neoplasms of the Prostate in Cancer Medicine. Holland J, Frei E (eds). WB Saunders, 1996.
- Johnson CS, McElwain MC, Ligh BW, Yu WD, Modzelewski RA, Trump DL, Getzenberg RH. Anti-proliferative effects of vitamin D and its analogus in rodent tumor models. In: Vitamin D: Chemistry, Biology and Clinical Applications., A.W. Norman, ed U Calif Printing, pp. 451-458, 1997.
- Haas GP, Triest J, Pontes JE, Trump DL. Nonsurgical Treatment of Adrenocortical Cancer in Principles and Practice of Genitourinary Oncology. Raghavan D, Scher HI, Leibel SA, Lange PH, eds. J.B. Lippincott Company, Philadelphia, 1997.
- Smith DC, Trump DL. Prostate Cancer in Geriatric Medicine, 3rd Edition. Cassel CK, Cohen HJ, Larson EB, Meier DE, Resnick NM, Rubenstein LZ, Sorensen LB, eds. Springer Verlag, New York, NY. pp. 305-315, 1997.
- Uskokovic MR, Trump DL, Getzenberg RH, and C.S. Johnson. Effect of vitamin D and vitamin D analogues in solid tumor model systems. Vitamin D Physiology, Molecular Biology and Chemical Application, M. Holick, ed., Humane Press, Totowa, NJ, pp. 431-445, 1999
- Johnson CS, Hershberger PA, Modzelewski RA, Bernardi RJ, McGuire TF, Rueger RM, Yu WD, Blum KE, and Trump DL. 1,25 Dihydroxycholecalciferol (calcitriol) as an anticancer agent: Preclinical Studies. Vitamin D Endocrine System, Structural, Biological, Genetic and Clinical Aspects, Norman A.W., Bouillon R., Thomasset M., ed. University of California Printing, Riverside, CA pp 461-468 (2000).
- Trump DL, Hershberger PA, Modzelewski RA, Bernardi RJ, Muindi J, Rueger RM, Yu WD, Egorin MJ, Blum KE, and Johnson CS. Clinical Development of Calcitriol and Calcitriol Analogues as Anti-cancer Agents. Vitamin D Endocrine System, Structural, Biological, Genetic and Clinical Aspects, Norman A.W., Bouillon R., Thomasset M., ed. University of California Printing, Riverside, CA pp 469-475 (2000).
- Trump DL. Prostate Cancer in Encyclopedia of Cancer, Second Edition, Volume 3. Elsevier Science, pp. 463-473, 2002.
- Schiff D, Trump DL, Wen PY. Neurologic Complications of Genitourinary Malignancies in Cancer Neurology in Clinical Practice. Schiff D and Wen PY, eds. Humana Press Inc., Totowa, NJ. pp. 327-338, 2002.
- Matin K, Trump DL. Prostate Cancer in Geriatric Medicine, 4th Edition. Cassel CK, Leipzig RM, Cohen HJ, Larson EB, Meier DE, Capello CF, eds. Springer Verlag, New York, NY, 2003.

22. Baar J, Trump DL. Adjuvant Therapy for Renal Cell Carcinoma in Renal and Adrenal Tumors -- Biology and Management. Belldegrun A, Ritchie AWS, Figlin RA, Oliver T, eds. Oxford University Press, Oxford UK, 2003
23. Chatta GS, Trump DL. Chemotherapy for Metastatic Urothelial Cancer in Urothelial Tumors. Droller MJ (ed). B.C. Decker Inc., December 2003
24. O'Connor T, Trump D. Endocrine Complications. In: Clinical Oncology, Third Edition. (Ed., Abeloff, M.D., Armitage, J.O., Niederhuber, J.E., Kastan, M.B. and W. Gillies McKenna.) pp. 1287-1296, 2004.
25. Fakih M, Sunga A, Trump DL. Reproductive Complications. In: Clinical Oncology, Third Edition (Ed., Abeloff, M.D., Armitage, J.O., Niederhuber, J.E., Kastan, M.B. and W. Gillies McKenna.) pp. 1269-1285, 2004.
26. Trump DL. Androgen Deprivation for Men with PSA-Only Failure Following Radical Prostatectomy: When? In: Management of Prostate Cancer. KB Cummings, ed. Marcel Dekker, New York, pp. 307-338, 2004.
27. Chatta GS, Trump DL. Systemic Chemotherapy for Metastatic Urothelial Cancer. In: Atlas of Clinical Oncology Urothelial Tumors. MJ Droller, ed. BC Decker Inc. Hamilton, Ontario, pp. 388-401, 2004.
28. Trump DL, Hershberger PA, Muindi J, Johnson CS. Clinical Development of Calcitriol and Calcitriol Analogues in Oncology: Progress and Considerations for Future Development in Vitamin D, Second Edition. D. Feldman, J.W. Pike & F.H. Glorieux (eds) Elsevier Science, San Diego, CA. pp.1741-1749, 2005.

PUBLISHED ABSTRACTS (2002-2008)

1. Muindi J, Peng Y, Rowley L, Krill D, Johnson CS, Trump DL, and Branch RA. Increased calcitriol oxidation in primary cultures of prostate cancer epithelial cells. Proc. Amer. Assoc. Cancer Res. 9, 2 (2002).
2. Ahmed S, Hershberger PA, Zuhowski EG, Egorin MJ, Trump DL and Johnson CS. Oxaliplatin activity in prostate cancer. Proc. Amer. Assoc. Cancer Res. 312, 62 (2002).
3. Hershberger PA, McGuire TF, Powell-Davis A, Johnson CS and Trump DL. Enhanced cytotoxicity of 1,25-dihydroxyvitamin D3/cisplatin combination in squamous cell carcinoma is associated with MEKK-1 up-regulation and increased apoptosis. Pro. Amer. Assoc. Cancer Res. 2157, 434 (2002).
4. Yu WD, McGuire TF, Hershberger PA, Trump DL and Johnson CS. Paclitaxel enhances 1,25 dihydroxyvitamin D3-induced apoptosis: inhibition of survival signals and up-regulation of MEKK-1 and p73. Proc. Amer. Assoc. Cancer Res. 2158, 434 (2002).
5. McGuire TF, Trump DL and Johnson CS. 1,25-dihydroxyvitamin D3 induces cytosolic accumulation of MEKK-1 before onset of apoptosis in a p38 MAPK-regulated manner. Proc. Amer. Assoc. Cancer Res. 2159, 435 (2002).
6. Zuniga ZV, Srivastava SK, Gibson G, Hershberger PA, Trump DL, Johnson CS, Singh SV and Foster BA. Isothiocyanates inhibit cell growth and induce apoptosis in prostate cancer cells derived from TRAMP mice. Proc. Amer. Assoc. Cancer Res. 3180, 640 (2002).
7. Xiao D, Srivastava SK, Zeng Y, Hershberger PA, Johnson CS, Trump DL and Singh SV. Allyl isothiocyanate suppresses in vitro proliferation of PC-3 and LNCaP human prostate cancer cells by inducing apoptosis and mediating G2/M arrest. Proc. Amer. Assoc. Cancer Res. 3184, 641 (2002).
8. Bernardi RJ, Johnson CS and Trump DL. ZD1839 (Iressa) a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), enhances the antiproliferative effects of calcitriol (1,25-dihydroxyvitamin D3) in squamous cell carcinoma: Effects on ERK and Akt. Proc. Amer. Assoc. Cancer Res. 3883, 783 (2002).
9. Srivastava SK, Xiao D, Lew KL, Kokkinakis DM, Hershberger PA, Johnson CS, Trump DL and Singh SV. Allyl isothiocyanate inhibits growth of PC-3 human prostate cancer xenografts in vivo in nude mice. Proc. Amer. Assoc. Cancer Res. 4994, 1008 (2002).
10. Muindi JRF, Modzelewski RA, Peng Y, Trump DL, Johnson CS. Plasma pharmacokinetics of high dose calcitriol in tumor-bearing mice. Proc. Amer. Assoc. Cancer Res. 44, 1747 (2003).
11. Yu W-D, McGuire T, Hershberger P, Trump DL, Johnson CS. Antiproliferative effects of calcitriol and doxorubicin in an SCC model: Increased apoptosis and up-regulation of stress signaling kinases. Proc. Amer. Assoc. Cancer Res. 44, 2729 (2003).
12. Muindi JR, Peng Y, Potter DM, Johnson CS, Trump DL. Pharmacokinetics of Liquid Palm Oil Calcitriol Formulation in Advanced Cancer Patients. Proc. Amer. Assoc. Cancer Res. 45, 399 (2004).
13. Fuller RW, Johnson CS, Trump DL. The effects of 1,25 dihydroxycholecalciferol in combination with

- dexamethasone on the androgen-dependent LNCaP prostate carcinoma model in vitro with varying concentrations of androgen. *Proc. Amer. Assoc. Cancer Res.* 45, 544 (2004).
14. Yu W-D, Hershberger PA, Muindi J, Fuller R, Kong R-X, Trump DL, Johnson CS. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo in a human pancreatic carcinoma model in association with increased apoptosis and decreased P-Akt. *Proc. Amer. Assoc. Cancer Res.* 45, 2200 (2004).
 15. Flynn G, Johnson CS and Trump DL. The effect of 1,25-dihydroxycholecalciferol (calcitriol) on tumor-derived endothelial cell (TDEC) proliferation and apoptosis. *Proc. Amer. Assoc. Cancer Res.* 45, 4100 (2004).
 16. Lew KL, Srivastava SK, Choi S, Xiao D, Zeng Y, Johnson CS, Trump DL, Lee YJ, Singh SV. Sulforaphane-induced cell death in human prostate cancer cells is initiated by generation of reactive oxygen species. *Proc. Amer. Assoc. Cancer Res.* 1568, 368 (2005).
 17. Chung I, Flynn G, Yu W-D, Wong MK, Johnson CS and Trump DL. The in vitro and in vivo effect of 1,25-dihydroxycholecalciferol (calcitriol) on tumor-derived endothelial cell (TDEC) and matrigel-derived endothelial cell (MDEC). *Proc. Amer. Assoc. Cancer Res.* 2037, 477 (2005).
 18. Fakhri MG, Johnson CS, Muindi JR, Black JD, Creaven PJ, Brattain M, Kepner JL, Trump DL. A Phase I and Pharmacokinetics (PK) Study of Intravenous (IV) Calcitriol and Gefitinib Assessing EGFR Pharmacodynamic Interactions through Serial Skin Biopsies. *Proc. Amer. Assoc. Cancer Res.* 3995, 941 (2005).
 19. Parise RA, Egorin MJ, Johnson CS, Trump DL, Nicolls M, Hershberger PA. Pre-clinical studies accessing the therapeutic potential of 1,25-dihydroxyvitamin D3 (1,25D3) as a treatment for non-small cell lung cancer (NSCLC). *Proc. Amer. Assoc. Cancer Res.* 4034, 951 (2005).
 20. Yu W-D, Hershberger PA, Lau Y-K, Muindi J, Kong R-X, Trump DL, and Johnson CS. Effect of ketoconazole with dexamethasone on 1,25-dihydroxycholecalciferol mediated anti-tumor activity in vitro and in vivo in the human prostate cancer PC-3 model; association with increased caspase-8 cleavage and apoptosis. *Proc. Amer. Assoc. Cancer Res.* 5338, 1261-2 (2005).
 21. Ma Y, Yu W-D, Kong R-X, Trump DL, Johnson CS. Role of non-genomic activation of PI3K/Akt and MEK/ERK1/2 pathways in 1,25D3-mediated apoptosis in SCC cells. *Proc. Amer. Assoc. Cancer Res.* 47, 723 (2006).
 22. Alagbala AA, Moser MT, Johnson CS, Trump DL, Posner GH, Foster BA. Mechanisms of vitamin D insensitivity in prostate cancer using TRAMP. *Proc. Amer. Assoc. Cancer Res.* 47, 3930 (2006).
 23. Yu W-D, Ma Y, Kong R-X, Trump DL, Johnson CS. Activation of a mitochondrial apoptosis pathway induced by calcitriol in combination with ketoconazole and dexamethasone in human prostate cancer PC-3 cells. *Proc. Amer. Assoc. Cancer Res.* 47, 4041 (2006).
 24. Muindi JR, Yu W-D, Engler K, Johnson CS, Trump DL. Inhibitors of 24-hydroxylase activity enhance systemic calcitriol exposure in preclinical animal models. *Proc. Amer. Assoc. Cancer Res.* 47, 2153 (2006).
 25. Chung I, Karpf AR, Muindi JR, Johnson CS, Trump DL. Epigenetic silencing of CYP24 in tumor-derived endothelial cells (TDEC) contributes to selective growth inhibition by calcitriol. *Proc. Amer. Assoc. Cancer Res.* 47, 1624 (2006).
 26. Alagbala AA, Moser MT, Johnson CS, Trump DL, Posner GH, Foster BA. Molecular Mechanisms of 1,25-Dihydroxyvitamin D3 Insensitivity in Prostate. *Proceedings of the 13th Workshop on Vitamin D Abstract #169*, pg. 37 (2006).
 27. Alagbala AA, Moser MT, Johnson CS, Trump DL, Foster BA. 1,25-Dihydroxyvitamin D3 and its analog (QW-1624F₂-2) prevent prostate cancer progression. *Proceedings of the 13th Workshop on Vitamin D Abstract #170*, pg. 95 (2006).
 28. Chung I, Karpf AR, Muindi JR, Johnson CS, Trump DL. Epigenetic silencing of CYP24 in tumor-derived endothelial cells (TDEC) contributes to selective growth inhibition by calcitriol. *Proceedings of the 13th Workshop on Vitamin D Abstract #25*, pg. 50 (2006).
 29. Chung I, Flynn G, Yu W-D, Johnson CS, Trump DL. Calcitriol-mediated differential anti-proliferative effects in tumor-derived endothelial cells as compared to non-tumor microvascular endothelial cells. *Proceedings of the 13th Workshop on Vitamin D Abstract #24*, pg. 166 (2006).
 30. Fakhri M, Johnson CS, Muindi JR, Creaven P, Trump DL. A Phase I and pharmacokinetics (PK) study of intravenous (IV) calcitriol and gefitinib in patients with refractory solid tumors. *Proceedings of the 13th Workshop on Vitamin D Abstract #23*, pg. 46 (2006).
 31. Muindi JR, Engler K, Fakhri M, Page R, Tennant B, Johnson CS, Trump DL. Increased systemic exposure after calcitriol treatment in woodchucks compared to mice and man. *Proceedings of the 13th*

- Workshop on Vitamin D Abstract #5, pg. 174 (2006).
32. Javle MM, Johnson CS, Muindi JR, Yu W-D, Pendyala L, Creaven P, Ross M, Brady WE, Ramnath N, Fakih MG, Smith P, Iyer RV, Trump DL. Phase I, pharmacokinetic (PK), pharmacodynamic study of paricalcetriol [19-NOR-1 alpha, 25-(OH)₂ D₂] in combination with gemcitabine [2',2' difluorodeoxycytidine] in patients with advanced malignancies. Proceedings of the 13th Workshop on Vitamin D Abstract #180, pg. 177 (2006).
 33. Ma Y, Yu W-D, Kong R-X, Trump DL, Johnson CS. Non-genomic activation of P13K/AKT pathway suppresses in 1,25 D₃-mediated apoptosis in a squamous cell carcinoma model system. Proceedings of the 13th Workshop on Vitamin D Abstract #26, pg. 81 (2006).
 34. Muindi JR, Nganga A, Engler KL, Coignet LJ, Johnson CS, Trump DL. CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activities in human prostate cancer cell lines. Proceedings of the 13th Workshop on Vitamin D Abstract #4, pg. 117
 35. Romano MA, Pera P, Engler KL, Muindi JR, Chanan-Khan A, Trump DL, Johnson CS. Calcitriol and paricalcetriol induce growth inhibitory effects in multiple myeloma in *in vitro* systems. Proceedings of the 13th Workshop on Vitamin D Abstract #172, pg. 85 (2006).
 36. Yu W-D, Ma Y, Lau YK, Kong R-X, Trump DL, Johnson CS. Calcitriol enhances anti-tumor activity of ketoconazole/dexamethasone *in vitro* and *in vivo* in human prostate cancer PC-3 model through caspase-8/caspase 6 and mitochondrial/AIF apoptotic pathways. Proceedings of the 13th Workshop on Vitamin D Abstract #9, pg. 183 (2006).
 37. Yu W-D, Hershberger PA, Muindi JR, Kong R-X, Javle J, Trump DL, Johnson CS. Calcitriol enhances gemcitabine anti-tumor activity *in vitro* and *in vivo* in a human pancreatic carcinoma model. Proceedings of the 13th Workshop on Vitamin D Abstract #173, pg. 23 (2006).
 38. Hidalgo A, Flynn G, Trump DL, Johnson CS, Onate S. Altered 1 α ,25(OH)₂D₃ induction of target genes in prostate cancer. Proceedings of the 13th Workshop on Vitamin D Abstract, pg. 163 (2006).
 39. Johnson CS, Trump DL. Vitamin D Biology and Lung Cancer. Proceedings of the 4th International Chicago Symposium on Malignancies of the Chest and Head & Neck. J Thoracic Oncol 1(8):876 (2006).
 40. Chung I, Seshadri M, Yu W-D, Khan MK, Trump DL, Johnson CS. In vivo function of vitamin D receptor (VDR) in tumor angiogenesis. Proc. Amer. Assoc. Cancer Res. 48, 4625 (2007).
 41. Chung I, Karpf AR, Nowak N, Kong R-X, Trump DL, Johnson CS. Tumor-conditioned media induces CYP24 epigenetic silencing and sensitivity to calcitriol in Matrigel-derived endothelial cells (MDEC). Proc. Amer. Assoc. Cancer Res. 48, 563 (2007).
 42. Ma Y, Yu W-D, Flynn G, Hershberger PA, Kong RX, Trump DL, Johnson CS. 1,25D₃ potentiates the cytotoxic effects of cisplatin through up-regulation of p73 and enhancement of apoptosis in squamous cell carcinoma cells. Proc. Amer. Assoc. Cancer Res. 48, 449 (2007).
 43. Nganga A, Engler K, Johnson CS, Trump DL, Coignet L, Muindi JR. CYP24A1 Polymorphisms and Splicing Variants Associated with Different Patterns of Vitamin D Metabolism in Human Cancer Cell Lines. Proc. Amer. Assoc. Cancer Res. 48, 732 (2007).
 44. Yu W-D, Ma Y, Engler K, Kong R-X, Muindi J, Trump DL, Johnson CS. 19-Nor-1,25(OH)₂D₂ (non-calcemic vitamin D Analogue) in conjunction with gemcitabine induces antiproliferative activity through the suppression of 24-hydroxylase activity and the enhancement of apoptosis in a human pancreatic carcinoma cell line. Proc. Amer. Assoc. Cancer Res. 48, 1911 (2007).
 45. Ma Y, Su B, Yu W-D, Kong R-X, Trump DL, Johnson CS. 1,25D₃ regulates adhesion, migration and invasion of squamous cell carcinoma cells. AACR Annual Meeting, April 12-16, 2008, San Diego, CA.
 46. Yu W-D, Ma Y, Kong R-X, Trump DL, Johnson CS. Calcitriol and taxotere suppress bone metastases in PC-3M-luc-C6 prostate cancer mouse model as monitored by bioluminescence imaging. AACR Annual Meeting, April 12-16, 2008, San Diego, CA.
 47. Luo W, Deeb KK, Trump DL, Johnson CS. Silencing of 24-hydroxylase in human prostate cancer by promoter methylation. AACR Annual Meeting, April 12-16, 2008, San Diego, CA.
 48. Johnson CS and Trump DL. Differences in epigenetic silencing of calcitriol-induced CYP24 gene expression in endothelial cells from the tumor microenvironment. 3rd Symposium Vitamin D Analogs in Cancer Prevention and Therapy, May 17-18, 2008, Krefeld, Germany.
 49. Trump DL and Johnson CS. Clinical development of high dose vitamin D in cancer: current status. 3rd Symposium Vitamin D Analogs in Cancer Prevention and Therapy, May 17-18, 2008, Krefeld, Germany.